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Type I interferon-stimulated genes (ISGs) have critical roles in inhibiting virus replication and 
dissemination. Despite advances in understanding of the molecular basis of restriction by ISGs, 
the antiviral mechanisms of many remain unclear. The 20 kDa ISG, ISG20, is a nuclear 3’-5’ 
exonuclease with preference for ssRNA, which has been implicated in the IFN-mediated restriction 
of several RNA viruses. While the exonuclease activity of ISG20 has been shown to degrade viral 
RNA in vitro, these findings have not been reconciled with proposed effects of ISG20 against 
RNA viruses that replicate in the cell cytoplasm. In the present study, we utilize a combination of 
an inducible, overexpression system for murine ISG20 and Isg20-/- mice to investigate mechanisms 
and consequences of ISG20-mediated restriction of alphaviruses. Overexpressed ISG20 primarily 
localized to Cajal bodies in the nucleus and potently restricted chikungunya virus and Venezuelan 
equine encephalitis virus replication by inhibiting the translation of infecting genomic RNA. 
However, degradation of viral RNAs was not observed. Translation inhibition was associated with 
an ISG20-induced upregulation of over 100 other gene products, many of which possess known 
antiviral activity. ISG20-responsive gene upregulation correlated with IRF3 activity among other 
transcription factors. Importantly, ISG20 modulated the production of IFIT1, an ISG that 
suppresses translation of RNAs possessing the type-0 5’ cap structure such as the alphavirus 
genome. Consistent with this, the replication and virulence of IFIT1-sensitive alphaviruses was 
significantly increased in Isg20-/- compared to congenic wild-type mice. Our findings establish an 
indirect role for ISG20 in the early restriction of RNA virus replication by altering regulation of 
other ISGs that inhibit virus translation and possibly other viral activities in the replication cycle. 
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PREFACE 
Viruses face significant challenges when infecting higher eukaryote hosts. Co-evolution of viruses 
and their host species has given rise to numerous host factors that act to restrict the replication and 
spread of the invading virus, while the viruses themselves have developed methods to evade these 
acquired responses to infection. Two primary systems exist to restrict virus propagation and 
dissemination and eventually clear the invading organism. The first hurdle faced by an invading 
pathogen is the innate immune response, which consists of a series of non-specific responses 
induced by recognition of non-self antigens. These responses may be cellular in nature, such as 
the killing action of natural killer cells and macrophages, or may be cytokine directed, such as the 
multi-targeted approach of the interferon response. In addition to these nonspecific responses, 
which serve to slow the advance of invading pathogens, an adaptive immune response is primed 
and directed to recognize and clear the invading pathogen utilizing pathogen-specific epitope 
recognition. These adaptive responses take longer to develop after the initial encounter with a 
pathogen, but typically establish pools of memory cells that can rapidly expand and clear infection 
more efficiently in the event of subsequent encounters with a serologically identical pathogen. 
1.0  INTRODUCTION 
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1.1 ALPHAVIRUSES 
Viruses in the family Togaviridae, genus alphavirus, have members known to infect many Orders 
of the animal kingdom. Many of these are arthropod-borne viruses (arboviruses), with a natural 
transmission cycle alternating between a reservoir species and an arthropod vector, typically 
mosquitoes. Of particular interest, numerous alphaviruses are known to cause disease in humans, 
either as a transmission-competent or dead-end host. Those alphaviruses known to cause disease 
in humans are grouped based on their historic geographic distribution, either as Old World or New 
World strains. While the geographic distribution tended to be restricted to their continent of origin, 
the continuing globalization and interconnectedness of human populations and vector-adaptive 
mutations to the viruses themselves has led to a spread of these viruses, particularly chikungunya 
virus, to a pandemic scale. Thus, it is prudent to group these more accurately under the type of 
disease caused, either arthritogenic or encephalitogenic. The historic Old World alphaviruses are 
known to cause arthritic disease, with the prototypic examples being Sindbis virus, chikungunya 
virus, Ross River virus and Semliki Forest virus. New World alphaviruses instead cause 
encephalitic disease and include eastern equine encephalitis virus, Venezuelan equine encephalitis 
virus, and western equine encephalitis virus, all of which are pathogens of interest to the 
Department of Defense due to the potential for misuse as bioweapons. 
1.1.1 Alphavirus Structure 
1.1.1.1 Genome Organization 
The alphavirus genome (Figure 1) consists of a single positive-sense RNA molecule between 11 
and 12 kilobases in length (1). The genome is capped with a type-0 7-methylguanosine-ppp cap at 
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the 5’ terminus – that is, it lacks a 2’ o-methylation of the terminal ribonucleotide present in most 
vertebrate RNAs (2-4). The 5’-non-translated Region (NTR) consists of considerable secondary 
structure and two conserved sequence elements, both facilitating cap-dependent translation of the 
viral RNA while reducing the exposure of the non-standard mRNA cap structure, and acting as a 
promoter for RNA synthesis (3, 5, 6). The terminal stem loop also plays a crucial role in evading 
IFIT1-mediated cap recognition of VEEV, simply by limiting access to the terminal nucleotide 
overhang (3, 7). Secondary stem-loop structures, which are essential for efficient genomic 
translation, continue through the  entire 5’-NTR and the start of the nonstructural gene coding 
sequence (8, 9).  
The non-structural genes are arranged as a single open reading frame coding for the 
replicase proteins, nsP1, nsP2, nsP3, and nsP4 in sequential order (10). The alphavirus genome 
encodes an opal stop codon between nsP3 and nsP4, which requires a read-through event to 
translate the full nonstructural polyprotein (11-13). Immediately following the nonstructural open 
reading frame is an approximately 40-60 nucleotide junction coding for a sub-genomic promoter 
on the negative-sense replicative intermediate RNA (10). Flanking the sub-genomic promoter 
region is another polyprotein open reading frame that is produced as a 26S RNA late in the 
replication cycle and consists of the structural gene products, capsid, E3, E2, 6K, and E1 (10).  
The 3’-NTR of the alphavirus genome varies significantly in length between individual 
alphavirus species, as short as 100 nucleotides in VEEV to over 700 nucleotides in some strains 
of CHIKV, and likewise the secondary structures also vary considerably between viruses (1). A 
common feature in the 3’-NTR is the presence of additional conserved sequence elements, which 
are often duplicated and play a major role in virus replication by promoting negative strand 
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synthesis (8, 9, 14). Notably, the NTR secondary structure gives rise to genomic RNA stability 
and potentially resistance from cellular degradation pathways. 
 
Figure 1: Chikungunya Virus Genome. 
1.1.1.2 Gene Products 
The alphavirus genome codes for nine in-frame gene products and one additional protein resulting 
from an inefficient frame shift during translation of the 6K protein sequence. These gene products 
are characterized as either structural proteins, producing the essential components for the core 
virion particle and its assembly, or the nonstructural genes involved in replication. The non-
structural proteins are produced as a single open reading frame, forming nsP123 or nsP1234, which 
results from the read-through of an opal stop codon present in most alphavirus genomes (11, 15). 
The cleavage of the nonstructural proteins by nsP2 is temporally regulated and dependent on the 
molar concentration of existing cleavage products of the nonstructural polyprotein (16-18). 
Processing of the structural polyprotein is carried out by a combination of cellular factors as well 
as an autoproteolysis event carried out by nascent capsid protein (1). 
The nonstructural proteins function primarily to form the replicase complex required for 
RNA genome replication and production of the 26S subgenomic RNA. The alphavirus nsP1 
encompasses two known activities, a guanine-7-methyltransferase domain and guanyltransferase 
Schematic representation of the chikungunya virus genome as a prototypic alphavirus depicts 
organization of the 49S genomic RNA with the replicative intermediate promoter site for the 26S 
sub-genomic RNA annotated. Predicted NTR structures, as calculated by mfold v.2 for 
East/Central/South African clade lineage CHIKV, are included. 
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domain for capping the positive-strand genomes (19-23). In addition to these known enzymatic 
activities, nsP1 serves as an anchor for the replicase complex to cellular membranes through a 
conserved palmitoylated residue (24-27).  
The nsP2 protein contains an RNA helicase domain in the N-terminal region, which 
functions to unwind double-stranded RNA regions during replication and transcription (28-30). 
Additionally, nsP2 contains RNA triphosphatase activity and has a catalytically-inactive 
methyltransferase domain that is thought to contribute to cytotoxicity within the host cell (31). 
Notably, nsP2 contains a cysteine protease domain with a unique fold that recognizes the three 
cleavage sites for the nonstructural proteins (32-34). The protease specificity is dependent on the 
molar concentration of the various nonstructural polyprotein intermediates or fully processed 
proteins (34). Beyond its role in polyprotein processing, nsP2 has also been suggested to act as a 
transcription factor for the synthesis of the subgenomic RNA (32, 35, 36). Of the nonstructural 
proteins, nsP2 is the only one to contain nuclear localization signals, and, with certain alphaviruses, 
up to 50% may be found in the nucleus (37-39). Within the nucleus, nsP2 disrupts macromolecular 
synthesis as a potent inhibitor of cellular innate antiviral responses (40-45). 
The activity of alphavirus nsP3 is not well characterized, though it does play an essential 
role in minus strand and 26S sub-genomic RNA synthesis (32, 46). A conserved macro domain is 
present in the N-terminal region of all alphavirus nsP3 proteins, which contains ADP-ribose 
phosphatase activity (47-51). The C-terminal domain of nsP3 is not well conserved between 
species, and varies considerably in length (52, 53). One constant feature in this region is the 
hyperphosphorylation of serine and threonine residues, leading to RNA binding characteristics, 
which may provide insight into its involvement in RNA synthesis (54, 55). Importantly, the non-
conserved regions of nsP3 have played a significant role in developing molecular tools to study 
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the alphaviruses. nsP3 is tolerant to large insertions, allowing for the inclusion of fluorescent and 
bioluminescent proteins, including enhanced green fluorescent protein and its derivatives, or ATP-
independent enzymes like nano-luciferase (56-60). Insertions in the nsP3 protein may last many 
rounds of replication before reversion and are only mildly attenuating to overall alphavirus growth 
(56). 
RNA-dependent RNA polymerase activity lies within the alphavirus nsP4 (32, 61). Cellular 
levels of nsP4 are highly regulated during alphavirus replication through the inclusion of an opal 
stop codon between nsP3 and nsP4 requiring an infrequent read-through event during translation 
in most alphavirus genomes (11). Additionally, an N-terminal tyrosine residue allows for 
accelerated degradation kinetics through the N-end rule of the cellular ubiquitin-degradation 
pathway, leading to a shorter half-life and reduced accumulation of nsP4 as well as functional 
replicase complex in infected cells (62). This tight regulation of nsP4 concentration is required for 
efficient virus replication, with alphavirus mutants that express nsP4 more efficiently showing 
attenuated replication kinetics in vitro (63).  
The subgenomic message transcribed from the alphavirus genome codes for the five 
canonical structural proteins and the transframe protein. The capsid protein is the structural 
component that forms the viral core particle, enclosing the RNA genome. Capsid contains a self-
proteolytic activity, and in the New World alphaviruses, is shuttled to the nuclear pore of infected 
cells (64, 65). New World alphavirus capsid protein has been suggested to play a role in 
macromolecular synthesis inhibition by blocking the nuclear pores in mammalian cells (43, 66-
68). After capsid, the three glycoproteins, E3, E2, and E1, are encoded in that order, with 6K 
encoded between E2 and E1. The E3 portion of pE2 functions primarily to aid in the folding and 
trafficking of E2 and the assembly of the glycoprotein spike structures, and is not incorporated in 
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the final virion particle (69-71). The mature E2 acts as the receptor binding protein, and exposes 
E1 upon cell entry (72-74). E1 serves as the membrane fusion protein, creating a pore through 
which the capsid is released into a newly infected cell (75-77). The alphavirus 6K protein is 
essential for proper spike formation on the final virion and likely plays a role in virus budding 
from infected cells (78-81). The most recently discovered alphavirus protein, the transframe 
protein, results from a frameshift extension during the translation of 6K and may play an additional 
role to that of 6K in the assembly of virus particles and virulence in vivo (82). 
1.1.1.3 Virion Structure 
The alphavirus virion is composed of an icosahedral capsid filled with a single copy of the full-
length positive-sense ssRNA genome. The capsid particle is surrounded by a host-derived lipid 
envelope studded with tightly arranged heterotrimers of the alphavirus glycoproteins, E1 and E2, 
plus trace amounts of 6K and transframe protein (1, 82-87). The capsid is composed of 240 copies 
of the capsid protein arranged as tetramers and hexamers forming the observed icosahedral particle 
arrangement with a triangulation number of 4 (88-90).  
1.1.2 Alphavirus Transmission/Replication Cycle 
Most alphaviruses can be classified in a broader group of viruses called arboviruses, referring to a 
lifecycle in which the virus propagates through an invertebrate arthropod host, and a natural 
vertebrate reservoir. An arthropod vector, typically a mosquito species, picks up the virus during 
a bloodmeal from a viremic vertebrate host. The virus crosses the midgut and replicates in the 
vector salivary glands to high titer and is transmitted subcutaneously in the infected mosquito’s 
saliva to a naïve host.  
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Once in a competent host, cellular replication of the alphaviruses begins with receptor 
recognition and endocytosis of the virus particle (91). Endosomes progress through the lysosomal 
pathway, triggering an acidification event of the vesicle contents, including the bound virus 
particle. This acidification event triggers a conformational change in the E1-E2 heterotrimer on 
the particle surface, exposing a membrane binding motif in the E1 glycoprotein, which allows 
envelope fusion with the acidified endosome (92). E1 protein homotrimerizes after fusion and 
forms cation exchange channels, elevating the pH of the cytoplasm in the immediate vicinity of 
the endosome (76, 93). The nucleocapsid core is released into the cytoplasm where the locally 
elevated pH facilitates the disassembly of the capsid and release of the positive-sense genome (94-
96). Stem-loop structures present in the 5’-NTR of the alphavirus genome prime interactions with 
cellular cap-dependent translation machinery, and initiate immediate translation of the viral RNA 
(91).  
A polyprotein forming three or four individual non-structural cleavage products, nsP123 
and nsP1234, is produced from the genomic RNA from the initial translation event, depending on 
read-through of an opal stop codon (UGA) present at the end of nsP3 (1, 11-13, 15). The 
unprocessed polyprotein proceeds with three cleavage events mediated by the protease domain of 
nsP2 (33, 34, 64). The first event is the cleavage of nsP4 from nsP123, releasing the RNA-
dependent RNA-polymerase (RdRp) (16). The nsP4-nsP123 complex is responsible for the 
replication of the positive-sense genome to a negative-sense replicative intermediate that will serve 
as a platform for positive strand synthesis and later, structural gene sub-genomic RNA synthesis 
(16-18, 97-99). Further cleavage of the nsP123 by the nsP2 protease results in a release of the nsP1 
methyltransferase/guanyltransferase capping enzyme (16, 18, 100). The complex of nsP1-nsP23-
nsP4 starts shifting virus polymerase activity toward production of progeny positive-sense 
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genomes plus a positive-sense 26S sub-genomic RNA, which codes for the structural components 
of the alphavirus (16, 18). Finally, trans-acting nsP2 protease cleaves nsP23, resulting in a 
complete shift away from negative-strand synthesis and strongly drives production of the sub-
genomic RNA and progeny full-length genomes (16, 18, 35, 36). This system of cleavage 
specificity, dependent on the molar concentration of existing cleavage products, allows for the 
temporal regulation of the RdRp complex and signals the critical timing events of the virus 
replicative cycle. Additionally, nsP4 has two intrinsic binding sites that recognize the promoter 
elements for either the full length genome, or the 26S subgenomic RNA, preferentially producing 
a 5-fold or greater molar excess of the 26S RNA over genomic RNA (101, 102). It is prudent to 
note that in addition to the viral nonstructural proteins, a number of cellular proteins, including the 
La antigen and multiple hnRNP proteins, have been implicated in aiding alphavirus replication 
and transitioning between phases of genome synthesis (103-113). 
Late in the replication cycle when RNA production has shifted primarily to the positive 
strand and sub-genomic RNA products, translation of the structural polyprotein commences. The 
capsid, pE2 (E3 and E2), 6K, and E1 proteins are produced in a single chain that is first processed 
by capsid self-cleavage (1). This one-time cleavage event exposes an endoplasmic reticulum (ER) 
insertion sequence, allowing the rest of the polyprotein to be processed through the cellular export 
system (114, 115). The pE2, 6K and E1 proteins are all produced as transmembrane proteins in 
the ER. Cellular processing of the growing peptide chain results in cleavage of pE2 into the soluble 
E3 and membrane-bound E2, which is incorporated in the mature virus particle (84, 116). At this 
time, 6K and E3 are also cleaved in the ER maturation pathway (117).  
As capsid protein accumulates, the core particle starts to form and incorporates the genomic 
RNA through the recognition of specific packaging sequences located in the nonstructural gene 
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region of the positive-sense RNA (118). The newly completed nucleocapsids transit to the cell 
membrane where capsomeres associate with the C-terminal domain of E2 complexed as 
heterotrimers made up of glycosylated E1 and E2 on the cell surface (119-121). As budding 
proceeds, the progeny virion is released as a mature infectious unit. 
 
Figure 2: Alphavirus Replication Cycle 
1.1.3 Reporter-expressing Alphaviruses 
Over the years, various molecular tools have been developed to study alphaviruses. The 
incorporation of a duplicate subgenomic promoter has been widely employed to express a 
functional transgene or biological reporters including bioluminescent enzymes or various 
fluorescent molecules (122, 123). The alphavirus nsP3 protein is also amenable to large insertions, 
Schematic representation of the alphavirus replication cycle from (14). Replicative steps are 
temporally annotated. Positive sense (black) and antisense (hatched gray) RNA species from 
each stage are annotated with their respective products.  
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and has been used to successfully express biological reporters (124-126). Recently, our lab has 
demonstrated that functional reporters may be included in the structural polyprotein through the 
inclusion of a self-cleaving picornavirus 2A-like peptide sequence from thosea asigna virus (TaV) 
(56). These TaV reporter viruses retain similar virulence to their unmodified parental viruses, the 
reporter genes have greater stability than their double promoter counterparts, and are resistant to 
selective pressure for deletion over several rounds of replication (56). Importantly, the 
combination of nsP3 and TaV-assisted structural expression of biological reporters allows us to 
monitor events at distinct stages of the alphavirus replication cycle, with nsP3 transgenes 
expressed immediately upon initial virus translation, and structural reporters produced after 
genomic replication has occurred. In addition to the infectious alphavirus reporters, non-replicating 
mimic RNAs with alphavirus 5’ and 3’ NTRs flanking a bioluminescent reporter have been used 
to examine genomic translation in isolation (127, 128). Lastly, replicative events limited to a single 
round may be studied in detail using replicons, packaged alphavirus RNAs that lack the 
subgenomic structural genes required for propagation and dissemination (129).  
1.1.4 Selection of Alphaviruses for Study 
SINV has gained the status of the prototypic alphavirus due to its relative ease of use under 
biosafety level 2 containment practices. However, SINV does not cause a significant health 
burden, and typically does not cause disease in humans (130). For this reason, we chose to focus 
our studies on a selection of both arthritogenic and encephalitogenic alphaviruses with a significant 
impact on human health. Our chosen arthritogenic alphavirus, CHIKV, has grown to global 
importance with recent outbreaks in the Indian Ocean territories and the Americas (131-134). 
While CHIKV is rarely fatal, the associated disease has caused a significant economic burden on 
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afflicted regions. Additionally, we chose to study two representative encephalitogenic 
alphaviruses, VEEV and EEEV. Both viruses are capable of fatal disease in humans and are high 
priority pathogens as determined by the United States Department of Defense. While closely 
genetically related, both VEEV and EEEV follow a different disease course, though each are 
capable of causing fatal encephalitis in humans and other vertebrates (125, 135, 136). Together, 
CHIKV, VEEV and EEEV serve as a broad representation of the geographically diverse 
alphaviruses with global human and veterinary health importance. 
1.1.5 Chikungunya virus 
CHIKV was first differentiated from concurrent outbreaks of dengue virus in eastern Africa 
following a 1952-1953 outbreak of the emerging pathogen in Tanganyika, now Tanzania (137-
139). At the time of the outbreak, the disease was known locally as “chikungunya,” a word 
stemming from another in the Kimakonde language, “kungunyala,” which describes the contorted 
posture frequently taken by individuals afflicted with the disease as a means to alleviate joint pain 
associated with virus infection (138). Due to the variable clinical manifestations of dengue virus 
infection and an apparent overlap in symptoms, there was difficulty assigning the outbreak to the 
emergence of a hitherto unknown virus. Of note, the new epidemic lacked certain clinical features 
of dengue such as pain associated with eye movements and there was an unusually high occurrence 
of chronic flaring joint pain, leading the medical investigators to explore other explanations for 
the outbreak.  
CHIKV is transmitted between primates, including humans, by Aedes mosquito species, 
and primarily relied on Aedes aegypti for urban transmission between humans in Africa and Asia 
(140-146). In 2004, a mutation to the E1 glycoprotein was identified in the East/Central/South 
 13 
African (ECSA) clade of CHIKV circulating on La Réunion island, which allowed highly 
competent transmission of CHIKV by the Aedes albopictus mosquito, leading to an epidemic of 
millions of cases in the Indian Ocean territories and eventually Europe (147-151). CHIKV has 
recently emerged in the western hemisphere with an outbreak starting in the Caribbean in 2013, 
and spreading to the North and South American mainland shortly thereafter (133, 134, 152). Of 
note, the outbreak in the Americas was initiated by the Asian clade of CHIKV, and does not 
demonstrate enhanced vector competence for Aedes albopictus (152). However, recently ECSA 
strains have also been locally detected in Brazil, with potential to acquire similar vector-adaptive 
mutations as those observed on La Réunion (153). 
1.1.5.1 Chikungunya Virus Disease in Humans 
CHIKV disease in humans is estimated to be subclinical in 16-18% of cases, presenting no 
symptoms, but positive serology from regional surveillance programs (131, 132). Onset of CHIKV 
is abrupt, characterized by high fever, polyarthralgia/polyarthritis, myalgia, general fatigue and 
headache (154-158). The polyarthralgia occurs symmetrically, and typically afflicts peripheral 
joints of the wrists, hands and ankles (154, 156). Polyarthritis occurs at a lower frequency – around 
40% of total cases – and is most apparent in the hands and feet (154, 156). In addition to the severe 
muscle and joint manifestations, CHIKV also causes a maculopapular rash of the extremities and 
sometimes the face in about 50% of those infected (154-157). Other clinical signs of disease 
include gastrointestinal distress, nausea, vomiting, and diarrhea (154, 156, 158). The debilitating 
pain associated with CHIKV causes significant disruption in regions with ongoing outbreaks, with 
more than 60% of individuals incapacitated for all or part of the clinical course of infection (159, 
160). While CHIKV rarely causes fatal disease, atypical hemorrhagic and neurological symptoms 
have occurred in a subset of hospitalized patients, and have resulted in death (154, 157, 158). 
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Following the acute phase of CHIKV, over half of afflicted individuals report ongoing 
rheumatic symptoms for a month or longer (160-162). Most frequently, musculoskeletal pain 
persists with some individuals developing rheumatoid arthritis or chronic inflammatory condition 
of the peripheral joints (162, 163). Following the 2007 outbreak of CHIKV in Italy, over 60% of 
follow-up cases reported lasting arthralgia or myalgia a year after primary infection (159). Despite 
several attempts, a consistent risk factor associated with persistent arthralgia and myalgia has not 
been identified, though old age and a high CHIKV antibody titer appear to be loosely correlated 
with disease severity and longevity (164-166). 
1.1.5.2 Chikungunya Virus Pathogenesis in Mice 
Select wild type adult mouse strains are sensitive to CHIKV infection and can be used for studying 
arthritogenic disease in vivo (167-169). Mice between 3- and 6-weeks in age of the inbred, Jackson 
Laboratories black-6 genetic background (C57Bl/6J), succumb to CHIKV disease, marked by high 
serum viremia from 1- to 3-days post infection and virus replication in skin, muscle, and visceral 
organs between 1 and 5 days (168). Adult mice do not lose weight throughout the course of disease. 
Notably, mice infected subcutaneously in the footpad experience marked swelling in the infected 
limb and concurrently demonstrate a pain reflex for the swollen limb (168). Swelling is biphasic, 
with a small peak around 2-days post infection, and a maximum cross-sectional area achieved 
around 6- to 7-days post infection (168). CHIKV is detectible in muscle, spleen, and lymph nodes 
for the duration of the 5-day viremia, and this tissue replication precedes the peak hind limb 
swelling (168).  
CHIKV pathology in the feet is characterized by edema and generalized infiltration of 
mononuclear cells in the synovial membranes, connective tissues and muscle (168). A generalized 
breakdown of synovial tissues is observed, while muscle and tendons appear to remain intact with 
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minimal cellular damage (168). Most other tissues appear normal, with mild lesions of infiltrating 
mononuclear cells in the lymph nodes, spleen and liver (168). Interestingly, mononuclear 
infiltrates in the connective tissues remain for weeks after other signs of disease have resolved 
(168). The mononuclear infiltrates observed are mostly monocyte/macrophage lineage cells and 
NK cells, and a reduction of the overall populations of these cells is sufficient to ameliorate disease, 
indicating an essential role in CHIKV-induced inflammation and arthritis (168). Furthermore, 
CHIKV induces a mild inflammatory cytokine response in mice, with some early production of 
IFN-γ, TNF-α, IL-6 and MCP-1, with virtually no IFN-α/β observed in some studies (168, 169). 
Nonfatal CHIKV infection in adult mice may mimic the typical disease course in healthy 
adult humans, but is not representative of the rare, more severe symptoms associated with CHIKV 
infection. Additionally, adult mice deficient for various signaling components of the IFN-α/β 
response, including receptor and signal transducers, exhibit exacerbated, uniformly fatal disease 
with WT, but not attenuated CHIKV (167, 169).  CHIKV is detectible in skin, muscle, and synovial 
tissues in these animals, with higher rates of replication than observed in WT mice (167, 168). 
Importantly, these mice progress to neurological disease, similar to the rare severe cases of CHIKV 
in humans (167). Additionally, neonatal mice younger than 6-days old may be used as a model for 
fatal CHIKV infection (167). CHIKV replicates in a similar manner in neonates to their adult 
counterparts, and typically progresses to systemic inflammatory response syndrome (SIRS) or 
neurological syndrome and death by 12-days post infection (167). Prominent cell targets in all 
three models of CHIKV infection include mesenchymal lineage cells like fibroblasts, osteoblasts, 
and myoblasts (167, 168). Monocyte macrophages have also been implicated as a primary target 
of infection, though their infectivity in vitro remains controversial, owing to the purity of virus 
preparations, suggesting these cells may not initiate receptor-mediated virus infection (167-170). 
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1.1.6 Venezuelan Equine Encephalitis Virus 
A 1938 outbreak of equine encephalomyelitis in Venezuela prompted the identification and 
characterization of a new virus related to the western and eastern varieties previously described in 
North America (171, 172). This virus was serologically distinct from the eastern virus that caused 
an outbreak in Canada and the United States earlier the same year (172). The first human cases of 
this newly identified disease were described in 1942 for two laboratory workers who had been 
working with the agent for two months, with no fatalities reported (136). Since this time, numerous 
large outbreaks of VEEV have occurred throughout South and Central America, involving tens of 
thousands of equine and human cases (173-177). VEEV is propagated in an enzootic lifecycle 
between multiple rodent species and mosquitos, occasionally spilling over to equines and humans 
(174, 178-180). In addition to its natural replication/transmission cycle, VEEV is a pathogen of 
particular interest due to its previous development as a biological weapon by the United States and  
Soviet Union (181). 
1.1.6.1 Venezuelan Equine Encephalitis Virus Disease in Humans 
VEEV is pathogenic in humans, causing a severe acute febrile illness, but  rarely fatality (182-
185). Only about 1% of human cases result in death, and most fully recover from disease (186). 
Following a 2- to 5-day incubation period, infected individuals are struck by a sudden febrile 
illness marked by malaise, chills, and a severe headache (178). This disease may be accompanied 
by nausea and vomiting or diarrhea, as well as myalgia focused in the upper legs and lower back 
(186).  Rare involvement of the central nervous system (CNS) typically presents as convulsions, 
somnolence, confusion and photophobia, with some patients progressing to stupor and coma (186). 
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For most, disease lasts about 4-6 days, followed by a week-long recovery period. However, some 
patients experience biphasic disease (186).  
In fatal cases of VEEV, severe edema is prevalent in the CNS, with congestion and 
meningitis apparent in most victims (185). Rare hemorrhage and vasculitis may also be observed 
in the brain (185). Brain tissue doesn’t show significant signs of encephalitis in most cases, and 
inflammatory cell infiltration is mild (185). However, VEEV causes widespread infection in the 
resident cells of the lymphatic tissues, resulting in high levels of follicle necrosis in lymph nodes, 
spleen and around the gastrointestinal tract (185). Virus-induced damage is observable in most 
other tissues, including liver, lungs and kidneys (185). Based on various clinical case studies and 
the histopathological evidence from fatal cases, VEEV disease is humans is best described as a 
systemic acute febrile illness with occasional neurological involvement in the CNS.  
1.1.6.2 Venezuelan Equine Encephalitis Virus Pathogenesis in Mice 
WT VEEV causes a uniformly fatal disease in adult mice that more closely mimics that observed 
in equines rather than humans (125, 187, 188). Despite the high level of CNS involvement, VEEV 
infection in mice parallels the systemic disease observed in humans, and may still serve as a model 
of fatal VEEV. Infected mice rapidly succumb to disease, exhibiting rapid weight loss and acute 
behavioral changes within 1-day post inoculation (125). Mice become hunched and ataxic early, 
with obvious piloerection or “ruffling” of fur after one day (125). As disease progresses, CNS 
involvement becomes evident with mice demonstrating signs of paresis and paralysis, and 
eventually becoming moribund by 5-days post infection (125). Average survival time is about 5-6 
days following subcutaneous inoculation of VEEV (125). 
VEEV rapidly replicates in mesenchymal cells and myeloid cells of the draining 
lymphatics (125, 188). Serum viremia peaks at 12- to 24-hours post infection, seeding infection in 
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the spleen, and other visceral organs (125, 188). At the time of peak viremia, VEEV strongly 
induces systemic production of IFN-α/β, which tapers off over the next two days of infection 
(125).  Histopathology reveals VEEV present in the pancreas, liver, spleen, spinal cord and brain 
at the time of death. VEEV infection in mice also results in a unique lymphotropism, similar to 
that seen in humans (187). VEEV replicates robustly in monocyte/macrophage cells, leading to its 
unique disease phenotype among alphaviruses (125). 
 Adult mice uniformly succumb to encephalitis, with prominent neurological deficits 
apparent (125, 187, 188). VEEV first reaches the brain between 1- and 3-days post infection, 
steadily replicating in the CNS (125, 187, 188) (data not shown). Peak titer is observed in the brain 
around 4-days post infection (125, 188). At this time, virus is present in the hippocampus, 
thalamus, brainstem and spinal cord, with mild inflammatory cell infiltration evident (187). By 
day 5, virus can be found in the cerebellum and cerebral cortex and immune infiltration is more 
apparent (187). At this time, virus begins to decline in the brain and other tissues until the time of 
death (125, 187, 188). Neuronal decay and sustained inflammation dominate in the brain following 
peak viral load, and are sustained until the time of death (187). 
1.1.7 Eastern Equine Encephalitis Virus 
In 1938, an outbreak of a hitherto unknown viral encephalomyelitis among equines in 
Massachusetts was reported (189). The virus was identified to be an eastern variety of a previously 
discovered virus from California in 1930 (189). Concurrent to the equine outbreak, several children 
in the surrounding area fell ill with a viral encephalomyelitis, later identified as the same virus 
found in horses (189-191). The newly discovered EEEV was noted to have twice the mortality rate 
of the previously identified strain in this outbreak (190). Since its discovery, EEEV has caused 
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sporadic outbreaks among horses and humans, with 5 to 25 human cases reported in North America 
each year (192). EEEV naturally circulates in passerine birds through Culiseta species, and is 
potentially maintained in snakes or other reptiles of endemic regions (193-196). Spillover to 
humans requires a bridge vector, including Aedes and Coquellitidia species, which are widely 
distributed across affected areas of the United States (193, 196, 197). 
1.1.7.1 Eastern Equine Encephalitis Virus Disease in Humans 
In humans, EEEV is clinically indistinguishable from most acute viral infections early on. A short 
prodromal phase lasting 5 days on average is typically accompanied by fever, headache, and 
nausea or vomiting, and is sometimes associated with abdominal pain (198). A longer prodrome 
is associated with more favorable clinical outcomes in pediatric patients hospitalized with EEEV 
infection (135). During this period, about 50% of individuals experience generalized malaise and 
weakness and can have non-focused muscle and joint pain (198). Onset of neurological symptoms 
is typically abrupt and followed by rapid health deterioration. While neurological signs vary, 
confusion is most common, with about 25% of patients presenting combinations of somnolence, 
focal weakness, seizures, and even meningitis (198). Once in the neurological phase of disease, 
about 90% of patients progress to stupor or become comatose, with the latter lasting several days 
(198). EEEV is fatal in about 30-70% of cases, and most who recover do so with mild-to-severe 
long-term neurological impairments (135, 198, 199).  
Laboratory results for patients with EEEV reveal elevated white blood cell counts and an 
infiltration of blood cells in the cerebrospinal fluid (135, 198). This also corresponds to a rise in 
cerebrospinal fluid protein content (198). Brain imaging on infected patients by MRI or CT reveal 
abnormal lesions throughout the brain, but most commonly associated with the meninges, cortex, 
basal ganglia and thalamus (135, 198). Postmortem brain pathology clearly shows signs of 
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meningoencephalitis with EEEV clearly detectible in the brain, primarily in neuronal cells within 
the lesions detected by imaging (135).  
1.1.7.2 Eastern Equine Encephalitis Virus Pathogenesis in Mice 
In adult mice, EEEV disease is characterized by limited viral replication in peripheral tissues 
followed by the onset of a uniformly fatal neurologic disease (125, 200, 201). Average survival 
time depends on the dose received, but typically falls between 4- and 6-days post subcutaneous 
inoculation (125, 200, 201). Mice do not show notable signs of disease for the first 2-3 days of 
infection, with no prominent weight loss, and normal observed behavior during this period (125). 
Around the fourth day of infection, health rapidly declines, with rapid weight loss, and behavioral 
abnormalities including hunching, and reduced motility (125). This rapidly progresses with all 
mice becoming moribund by 5-days post infection (125, 200, 201). 
Following subcutaneous inoculation, EEEV replicates locally in primarily mesenchymal 
cells, including fibroblasts, osteoblasts, and myocytes (125, 200, 201). Virus is present in the 
draining lymphatics, but unlike VEEV, does not replicate (125, 200). This restricted cellular 
tropism is due to the presence of four conserved miRNA binding sites located in the 3’-NTR of 
EEEV, which prevent replication in macrophages and dendritic cells (127). Functionally, this 
restriction serves to evade the early IFN-producing immune response and contributes to the high 
pathogenicity observed with EEEV infection (127). Replication of EEEV in mesenchymal cells 
continues throughout the course of infection (200). After 18-24 hours, EEEV reaches peak serum 
viremia, seeding additional sites of replication (125, 200, 201).  
Around 24-hours post infection, virus first appears in the brain, with focused regions of 
replication around the somatosensory cortex (125, 200). EEEV replication in the brain in the first 
two days of infection is highly variable between mice (200). However, by 3- to 4-days post 
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infection, uniform replication is observed throughout the thalamus, midbrain and cerebral cortex, 
with virus detectible in most regions (200). This period of peak replication in the brain corresponds 
to declining viral titers systemically (125, 201). Among the alphaviruses, EEEV is uniquely 
neurovirulent, owing this phenotype to its ability to bind heparan sulfate, aiding in binding and 
entry into neuronal cells (202). Damage to brain tissue is evident at the time of death, with 
significant necrosis observed and mild immune infiltrates of neutrophils and eosinophils (200). 
1.2 TYPE I INTERFERON  
Host organisms have evolved a complex network of cytokine and cell-based responses to identify 
and clear microbial infections. Viral and bacterial structures and replicative intermediates can 
serve as pathogen-associated molecular patterns to trigger a broad, non-specific response aimed at 
restricting growth of the invading microorganism and priming the cellular innate and adaptive 
immune responses that eventually clear the infection. The first innate immune cytokine 
characterized was broadly named interferon (IFN) for its ability to interfere with the growth of 
influenza A virus, though it was later identified as just one of several cytokines with similar activity 
(203). There are three known types of IFNs, all class II α-helical cytokines, classified as type I 
through type III for the receptors they utilize. Both type I and type III consist of multiple members 
and share a common downstream signaling pathway, while IFN-γ is the only type II IFN. In 
humans, the functional type I IFNs consist of 13 subtypes of IFN-α, IFN-β, IFN-ε, IFN-κ, and 
IFN-ω (204). Due to cell-type restrictions of several these cytokines, however, immunological 
reference to type I IFN specifically refers to the subtypes of IFN-α/β. Unlike IFN-γ, which is 
produced primarily by T-cells and natural killer (NK) cells, type I IFNs may be induced and signal 
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in most cell types and act as a rapid first line of defense in both the infected cell and neighboring 
cells through autocrine and paracrine signal induction (204). Likewise, IFN-λ1, -λ2 and -λ3 signal 
through a distinct cell surface receptor that is primarily restricted to epithelial cells (205-207). 
1.2.1 Interferon Induction in Alphavirus Infection 
Host cells constantly sample their environment for pathogen-associated molecular patterns 
(PAMPs) through the recognition of non-self nucleic acids, proteins, lipids or polysaccharides. 
Nucleic acid sensing pattern recognition receptors (PRRs) identify RNA in atypical forms and 
locations such as double-stranded helices and 5’-triphosphate RNA associated with virus 
replication or localized to endosomes within the cell, as well as DNA present in the cytoplasm or 
endosomes. Likewise, specific bacterial-associated antigens such as lipopolysaccharide can trigger 
a separate receptor, TLR4, and activate the production of IFNs. In total, there are ten Toll-like 
receptors in humans – eleven in mice – named for the original Drosophila homologues. These are 
complemented by the RIG-I-like receptors (RLR), RIG-I, MDA5 and LGP2, as well as cGAS and 
other cytoplasmic DNA-sensing molecules that signal through the stimulator of interferon genes 
(STING). 
The receptor that identifies the PAMP determines the specific mediators of IFN induction. 
In the case of alphavirus replication, double-stranded RNAs (dsRNAs) are present in the cytoplasm 
at all stages of the replication cycle. Additionally, nascent 5’-triphosphate ssRNA is present and 
may serve as an additional PAMP for alphavirus infection. These cytoplasmic RNAs are detected 
by MDA5 and potentially RIG-I, inducing a conformational change and an association with 
MAVS on the mitochondria (208-210). MAVS activation leads to a cascade of phosphorylation 
events with TBK1 and IKKε, which in turn activate the interferon regulatory factors, IRF3 and/or 
 23 
IRF7, depending on the cell type (211-214). Poly-phosphorylated IRF3 dimerizes and translocates 
to the nucleus, where it assembles on the promoters of IFN-α4/β in non-myeloid cells along with 
ATF-2, c-Jun, CBP-p300, NF-κB and the RNA Polymerase II transcription machinery (215).  
 
Figure 3: Induction and Signaling of IFN-α/β 
IRF3-mediated activation of IFN-α4/β contributes an initial production of IFN in response 
to microbial infection. Subsequently, IRF7 is induced by downstream IFN signaling, resulting in 
a feedback loop where IRF7 is the primary driver of secondary IFN production, that includes 
several other IFN-α genes (217, 218). While most cell types are capable of producing and 
responding to IFN-α/β, the largest production of serum IFN is often attributed to a class of cells 
called plasmacytoid dendritic cells (pDCs) (219). IFN-α/β is induced in pDCs, and other myeloid 
Cellular induction pathways for IFN-α/β production and downstream signaling. IFN produced 
from stimulated cells may act through paracrine signaling as shown, or autocrine signaling. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews | Immunology, (216), 
copyright 2015.  
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cells, through constitutively expressed IRF7, bridged through MyD88 (220). In the case of pDCs, 
viral components are sampled from the environment and the endosomal dsRNA-sensing receptor 
TLR7 signals through MyD88 which is pre-associated with IRF7 for rapid signal transduction in 
these cell types (221-224). However, despite their crucial role in other viral infections, pDCs do 
not appear to play a major role in the IFN response to alphavirus infection in vivo (225, 226). 
1.2.1.1 Cytosolic RNA Sensing Pathogen Recognition Receptors 
Virus-associated RNAs are a universal identifying characteristic for cells to initially detect 
infection. As such, eukaryotes have evolved several non-redundant mechanisms for detecting 
foreign RNA in the cytosol and endocytic vesicles. Within the cytosol, two known functional 
RLRs, RIG-I and MDA5, act in concert to detect non-self RNA structures and signal the cascade 
of initial innate immune responses. These proteins are members of the DExD/H box RNA 
helicases, which also includes the related LGP2 helicase with yet unknown function in antiviral 
signaling (227-229). RLRs are present at a low resting state, and are upregulated by IFN signaling 
to increase sensitivity after infection is first identified (227, 230). In addition to the cytosolic RNA 
sensors, TLR3 detects dsRNA in endocytic vesicles, and TLR7/8 detects ssRNA sequences within 
endosomes. While the RLRs are ubiquitously expressed in most tissues, the TLR RNA sensors are 
more restricted in their expression. 
Both RIG-I and MDA5 are composed of three distinct functional domains, containing two 
caspase activation and recruitment domains (CARD), the DExD/H box RNA helicase responsible 
for binding RNA substrates, and a repression domain at the c-terminus (227-229). Prior to substrate 
binding, the CARD and repressor domain interact to form a closed conformation of the RLR, 
preventing binding and signaling with the MAVS adaptor protein (229, 231). The RNA substrate 
is recognized through a binding event in the repressor domain, releasing the CARDs for 
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oligomerization and binding with MAVS (209, 232-234). In RIG-I, the repressor activity is 
regulated intramolecularly. However, MDA5 does not autoregulate its activity, and requires an 
additional repressive signal, potentially through the related LGP2, which lacks the N-terminal 
CARD (235). 
RIG-I and MDA5 both bind cytoplasmic RNA, but show preference for different 
structures. RIG-I has been characterized to respond to numerous RNA substrate specificities, 
including single and double stranded RNA motifs that contain a 5’-triphosphate (235, 236). The 
5’-triphosphate appears to be a required motif for most RNA recognition, with reduced signaling 
activity resulting from diphosphate or monophosphate ends (237, 238). However, RNA 
degradation products from RNase L, which lack a 5’-triphosphate, but contain a 3’-monophosphate 
can also induce signaling through RIG-I (239, 240). In addition to the phosphate specificity of 
RNA substrates, RIG-I also preferentially responds to short RNAs with at least a short double-
stranded region or a stretch of poly-uridine sequence interspersed with cytosine residues (235). 
RIG-I recognition of cytoplasmic dsRNA is not limited to 5’-triphosphate RNA, but may also 
include type-0 capped RNA species as well (235, 241). In contrast, MDA5 is much more specific 
to dsRNA and lacks the ability to recognize the negatively charged phosphate moieties that define 
RIG-I binding (242). Instead, the C-terminal domain recognizes dsRNA motifs with a preference 
for blunted ends rather than those containing overhangs. 
1.2.1.2 IRF3 Activation and Transcriptional Activity 
IRF3 is the primary transcription factor associated with the induction of IFN-α4/β following 
pathogen recognition in non-myeloid cell types. IRF3 contains both nuclear localization and 
nuclear export signals, with the latter dominating, resulting in a steady-state distribution mostly in 
the cytoplasm of non-infected cells (243). Upstream signaling events result in TBK1 and IKKε 
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polyphosphorylation of serine residues in the IRF3 C-terminal domain (244-246). Resulting from 
this polyphosphorylation, IRF3 either homodimerizes or heterodimerizes with activated IRF7, 
blocking the nuclear export signal, and shuttles to the nucleus where it associates with CBP and 
p300 (246). In addition to enhancing transcription of IFN genes, IRF3 recognizes specific 
interferon stimulation response elements within its target promoters, specifically a sequence of 
GAAANNGAAANN, which is present in both the IFN-α4/β promoters as well as several other 
IFN stimulated genes (ISGs). One study with a constitutively active mutant of IRF3 has revealed 
multiple ISGs with known antiviral activity to be upregulated by IRF3, including members of the 
IFIT family of antiviral proteins, the ubiquitin-like ISG15, 2’-5’ OAS, IFI44, and GBP2 (247). 
1.2.1.3 Other RNA Pattern Recognition Receptors 
In addition to the cytosolic RNA PRRs, IFN can be induced through the activation of TLRs, the 
cytoplasmic DNA sensor, cGAS, and the cytosolic peptidoglycan NOD-like receptors. In 
particular, three TLRs may play an important role in viral detection, again through specific binding 
to RNA. While the membrane-bound TLRs may localize either on the cell surface or within 
endosomes, the RNA-sensing TLR3/7/8 are all located within endosomes. TLR3 and TLR7 have 
both been implicated in downstream signaling in the context of alphavirus or alphavirus replicon 
infections and play a protective role in mice (248, 249). TLR3 detects dsRNA intermediates 
present in endosomes, while TLR7 and TLR8 show specificity to ssRNA (222-224). TLR3, while 
ubiquitously expressed in most cell types, exhibits differential signaling between myeloid and non-
myeloid lineage cells. In particular, macrophages and dendritic cells, while able to respond to 
TLR3 ligands, do not induce IRF3 signaling (250). In contrast, TLR7 and TLR8 are the primary 
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drivers of IFN-α/β production in myeloid cells, particularly pDCs, and are restricted in expression 
primarily to pDCs, monocyte/macrophages and B-lymphocyte cells (251). 
While PRR signaling for IFN production is an important function for this class of 
molecules, some PRRs may carry out additional antiviral functions for the cell. The IFN-inducible 
RNA-dependent protein kinase, PKR is activated by binding dsRNA through its N-terminal 
domain, resulting in auto-phosphorylation and activation (252-256). Instead of inducing an 
IRF3/IRF7 mediated IFN production like the other RNA PRRs discussed, activated PKR 
phosphorylates the eukaryotic initiation factor eIF2α, blocking cap-dependent initiation of 
translation (257). PKR activity may also lead to the activation of NF-κB through phosphorylation 
of the inhibitory IκB subunit (258-261). Lastly, PKR may play an additional non-redundant role 
in IFN production in response to some viruses, including some alphaviruses, by stimulating poly-
adenylation of IFN mRNAs in the cytoplasm and by independently activating MDA5 (262-264). 
Similar to PKR, another cytoplasmic IFN-induced PRR, 2’-5’-oligoadenylate synthetase 
(OAS), demonstrates a targeted antiviral activity rather than directly stimulating IFN production 
in response to pathogen detection. OAS binds dsRNA substrates in the cytosol and synthesizes 
oligomers of 2’-5’-linked adenosine or guanosine (265, 266). These substrates act as a second 
messenger for the activation of RNase L, a latent endonuclease that may either serve to directly 
cleave viral RNAs or generate additional stimuli for RIG-I signaling and eventual IFN-α/β 
production (239, 267). However, the extent of the contribution of the combined mechanisms of 
PKR and RNase L is in question as mice deficient in both show little enhanced susceptibility to 
multiple viruses, including alphaviruses (268, 269). 
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1.2.1.4 Additional Induction Pathways 
IFN induction from cytosolic PRRs follows a MAVS-centric signaling pathway. TLR induction 
of IFN, however, transduces the receptor signal through the adapters TRIF or MyD88 depending 
on the TLR, and ultimately the cell type in question (270, 271). In the case of RNA-sensing TLRs, 
TLR3 signals through a recruitment of TRIF and subsequent phosphorylation and activation of the 
TBK1/IKKε signaling cascade observed with the cytosolic RNA sensors (244, 270, 272). TLR7/8, 
the primary inducer of IFN in pDCs, recruits MyD88, which phosphorylates IRAK, leading to an 
association with TRAF6 (271-275). Activated TRAF6 initiates a cascade of signaling events 
through additional IκB kinases leading to the phosphorylation of the IκB inhibitor of NF-κB (276-
281). NF-κB proceeds to initiate the transcription of numerous innate and adaptive immune 
regulatory factors, including the production of IFN-α/β (282). 
1.2.2 Interferon Signaling through JAK/STAT 
Most healthy cell types can respond to IFN-α/β signaling. Secreted IFN-α/β binds to the IFN-α 
receptor complex (IFNAR), a heterodimeric transmembrane cytokine receptor consisting of the 
IFNAR1 and IFNAR2 subunits, to initiate autocrine or paracrine signaling through the JAK/STAT 
pathway (283). The cytosolic end of the IFNAR1 subunit is associated with the tyrosine kinase 
TYK2 and the IFNAR2 subunit with JAK1, which are activated upon ligand biding and result in 
the phosphorylation of STAT1 and STAT2 (284-287). The two phosphorylated STAT proteins 
form a heterodimer and recruit cytosolic IRF9 to form the IFN stimulated gene factor 3 (ISGF3) 
complex (288). The functional ISGF3 complex traverses the nuclear pore where it associates with 
IFN stimulation response elements (ISRE) within the promoters of target genes to initiate 
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transcription (289, 290). In addition to this canonical signaling pathway, IFN-α/β can activate 
additional STAT proteins through IFNAR, and may lead to additional pathway activation, 
including MAPK and mTOR signaling (291-295).  
Much like the IFN-α/β signaling cascade, IFN-λ is recognized by a heterodimeric type III 
IFN receptor complex consisting of the IFN-λ receptor 1 and IL-10 receptor 2 (IFNLR1/IL10R2), 
which are associated intracellularly with JAK1 and TYK2 (296-298). Within the cell, IFN-λ results 
in the same signaling cascade through STAT1 and STAT2, leading to ISGF3 complex formation 
(299). Due to the shared cellular signaling pathway between both IFN-α/β and IFN-λ, a common 
pattern of ISGs are induced by both cytokines (300, 301). In contrast to the type I and type III 
IFNs, IFN-γ signals through the heterodimeric IFN-γ receptor subunits 1 and 2 (IFNGR1/IFNGR2) 
coupled intracellularly with JAK1 and JAK2 (302, 303). Activation results in tyrosine 
phosphorylation of STAT1, which homodimerizes and translocates to the nucleus (304, 305). IFN-
γ JAK/STAT signaling does not involve additional factors, namely IRF9, and enhances 
transcription of target ISGs through direct interactions between STAT1 and the gamma activation 
sequence (GAS) in target gene promoters (305, 306).  
1.2.2.1 Downregulation of Interferon Signaling 
IFN signaling results in the induction of hundreds of IFN-stimulated genes (ISGs), many of which 
function to restrict microbial infections, and upregulates multiple stress responses that may lead to 
cell death. As such, IFN signaling is tightly regulated within the cell to avoid overexposure to pro-
apoptotic and inflammatory responses. Cytokine signaling responses may be regulated by receptor 
internalization or direct inhibition of the signaling pathway in activated cells. The mechanisms of 
IFN signaling control include disruption of ISG transcription through polymerase pausing, 
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transcript degradation through miRNA expression, and direct protein-mediated interactions with 
the upstream signaling components (307-310). Activated JAK1 is directly targeted by two proteins 
of the suppressors of cytokine signaling family, SOCS1 and SOCS3, to prevent additional 
activation of STAT proteins (311, 312). A specific interaction with phosphotyrosine residues of 
the catalytic loop of JAK1 initiate binding of SOCS1/3, immediately blocking catalytic activity 
(312). SOCS proteins have also been implicated in direct binding to IFNAR, blocking the 
recruitment of STAT to the receptor-associated kinase (313, 314). Other mechanisms have been 
suggested in SOCS control of IFN induction and signaling, including targeting of TLR signaling 
adapters for proteasomal degradation to downregulate NF-κB signaling (315). 
Another mechanism of desensitization to IFN signaling occurs through the induction of the 
ISG, USP18. USP18 is an isopeptidase that functions much like a de-ubiquitinating enzyme, but 
primarily acts to remove the ubiquitin-like ISG15 through a process called deISGylation (316). 
While USP18 functions to remove ISGylated proteins from the proteasomal degradation pathway, 
this activity was not required for inhibition of sustained IFN signaling (317). Instead, USP18 
employs a similar binding affinity for IFNAR2 as SOCS2 and blocks the receptor interaction with 
JAK1, silencing downstream signaling events (317-320). Combined, these methods act in concert 
to temporally regulate IFNAR signaling, and desensitize cells to a prolonged IFN-α/β response. 
1.2.2.2 Alphavirus Suppression of Interferon Signaling 
Alphaviruses do not uniformly induce IFN-α/β in vivo, and induction is associated with the degree 
to which each strain is capable of infecting lymphoid tissues (14, 321). Likewise, the alphaviruses 
differentially resist the antiviral effects of IFN signaling (see Table 1). It has been demonstrated 
that alphaviruses may overcome this effect by inhibiting cell macromolecular synthesis at both the 
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transcriptional and translational levels (40, 44, 68, 322, 323). The alphaviruses appear to 
accomplish this activity through multiple proteins, including nsP2 and capsid (40, 42, 43, 66, 68). 
Interestingly, alphavirus resistance to IFN-α/β corresponds to the degree to which their respective 
proteins can inhibit infected cell macromolecular synthesis in the presence of existing IFN-priming 
(40). Additionally, specific antagonism of IFN signaling has been demonstrated with both the nsP1 
and nsP2 protein directly interfering with JAK/STAT induction (323-327). Together, these 
activities function to mount some resistance to IFN signaling, and may account for differences in 
pathogenicity in humans and animal models of infection. 
1.3 INTERFERON STIMULATED GENES 
The primary result of IFN-α/β activation of the JAK/STAT pathway is the targeted upregulation 
of ISGs through transcriptional activation. ISGs represent a diverse class of gene products 
composed of more than 300 known proteins, many of which have antiviral activity by directly 
targeting specific pathways and functions involved in the virus replication cycle (328, 329). Early 
studies in the field of ISG research were dominated by the RNA-dependent protein kinase, PKR, 
or the latent RNA endonuclease, RNaseL and its activator, 2’-5’-OAS (252, 253, 330). These three 
components represent a substantial pathway for disrupting viral protein translation, and potential 
degradation of RNA genomes and gene products recognized by regions of dsRNA. Additionally, 
Mx GTPases were well characterized for their inhibition of influenza virus and several other RNA 
viruses through direct interactions with their respective nucleocapsid proteins (265, 266, 331-338). 
While these proteins were thought to produce the majority antiviral effect of IFN signaling, more 
recent work has identified numerous PKR/RNaseL independent pathways for virus restriction and 
 32 
the mechanism of action has been a major target of investigation in the field of molecular virology 
(3, 268, 329, 339-343). 
In mouse models, the alphaviruses are differentially susceptible to the ISG effectors of the 
IFN-α/β response. At one end of the spectrum, SINV induces and is highly susceptible to the 
effects of IFN-α/β priming, leading to reduced pathogenesis in healthy adult animals (14). EEEV 
is highly susceptible to IFN-α/β priming, but does not induce a systemic IFN response in vivo due 
to a restriction of cell tropism (14, 125, 127, 344). CHIKV does not induce a strong systemic IFN 
response in mice and is mildly resistant to the ISG effectors of IFN-α/β (168, 345). VEEV, 
however, induces a significant systemic IFN response, but is much more resistant to its effects than 
the other alphaviruses (14, 40, 125). A summary of alphavirus IFN-sensitivity is shown in Table 
1. Due to the different avoidance/antagonism strategies employed by these viruses, alphaviruses 
represent a particularly useful repertoire for the mechanistic study of ISGs and the IFN-α/β 
response. 
 INDUCES IFN IFN PROTECTION FROM CPE 
VEEV ++++ + 
CHIKV ++ ++ 
SINV +++ ++++ 
EEEV + +++ 
Table 1: Alphavirus induction and susceptibility to IFN 
Relative induction of serum IFN at 24 hours p.i. and relative protection from virus-induced 
cytopathic effect from IFN-α/β priming is qualitatively compared between members of the 
alphavirus genus. Data are from (14) and unpublished data. 
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1.3.1 Anti-alphaviral Interferon Stimulated Genes 
The severity and pathogenic outcomes of numerous alphavirus infections are broadly controlled 
by the IFN-α/β response (14, 167, 168, 323, 344-346). Identifying the individual effectors of the 
IFN-α/β antiviral state that contribute to disease attenuation and decreased morbidity/mortality is 
of particular interest (329, 339, 340, 347). In particular, knowledge of the function of innate 
antiviral responses to alphavirus infection may lead to identification of virus vulnerabilities as well 
as a better understanding of virus attenuation to aid in the design of rationally designed vaccines 
(3). 
Previous work studying host-pathogen interactions between ISGs and the prototypic 
alphavirus, SINV, has demonstrated a vital role for ISGs independent of PKR and RNase L (339). 
In this study, 44 putative anti-alphaviral ISGs were identified for follow-up assessment. Another 
study used both VEEV and CHIKV among other viruses to screen pan-tropic antiviral effectors, 
ultimately identifying multiple upstream signaling components including IRFs and PRRs (329). 
To date, ten ISGs have been assessed for their antiviral activities against one or more alphaviruses, 
and represent a wide range of strategies for inhibiting replication and dissemination. 
The zinc-finger antiviral protein (ZAP) was originally discovered in similar screening 
efforts to identify putative antiviral genes using Moloney murine leukemia virus (348). Follow-up 
studies using SINV revealed a potent inhibitory effect of ZAP on alphavirus replication (340, 349-
351). While the full significance of ZAP as an antiviral effector is still not entirely clear, it appears 
to bind viral RNA directly, and act as a scaffold for recruiting additional factors in complex with 
the virus genome (349-351). Interestingly, ZAP antiviral activity has not been observed in 
flavivirus or enterovirus infection, suggesting some degree of specificity in RNA targets (126). 
 34 
Multiple ISGs involved in protein processing have been demonstrated to restrict 
alphaviruses. The endoplasmic reticulum-localized viperin was shown to significantly impact both 
SINV and CHIKV replication, with CHIKV infection in viperin-null mice resulting in elevated 
serum viremia and increased disease severity (340, 352). Another protein modifying ISG, ISG15, 
has an impact on alphavirus replication and associated disease (340, 353, 354). ISG15 is a 
ubiquitin-like polypeptide that is ligated to target proteins by multiple E3 ligases via ISGylation 
and may function to either block protein activity or even enhance stability and resistance to 
degradation (238, 355-359). In addition to its protein modifying activities, ISG15 may play a role 
in cytokine signaling with downstream antiviral effects, independent of its conjugation to viral or 
cellular proteins (354). Related to the activity of ISG15, the antiviral E3 ligase, TRIM25, has a 
similarly potent antiviral activity, and may synergistically act with ZAP (360). TRIM25 in 
particular, has been shown to function both in ISGylation as well as ubiquitination of the RIG-I 
CARD, a process necessary for robust downstream signaling (361). 
Alphavirus translation is a prominent target of antiviral activity (339). Recent work with 
members of the poly-(ADP-ribose) polymerase (PARP) family of proteins has elucidated a role in 
translation inhibition of both VEEV and cellular proteins (362, 363). Additionally, the interferon 
inducible protein with tetratricopeptide repeats 1 (IFIT1) has been characterized to exhibit 
prominent anti-alphaviral activity, leading to a mechanistic understanding of how it restricts 
translation (3, 340, 364).  
In addition to ISGs that restrict replication events within the cell, two known ISGs have 
been demonstrated to restrict the alphavirus entry and egress pathways (365, 366). IFITM3 is a 
transmembrane ISG that modestly inhibits alphavirus entry by restricting pH-dependent fusion 
within the endosome following receptor binding and internalization (366). BST-2 restricts virus 
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egress by tethering budding virions, preventing escape from the infected cell and slowing the 
progress of alphavirus spread (365). However, WT alphaviruses appear to have mechanisms to 
overcome this mode of virus restriction, with CHIKV nsP1 specifically binding BST-2 while 
simultaneously downregulating it’s expression at the mRNA level (365).  
The effects of two ISG nucleases have been explored in relation to alphavirus infection 
(340, 367). OAS/RNase L restrict virus replication through the direct endonuclease activity of 
RNase L on viral RNA. However, as mentioned above, the role of OAS/RNase L is likely not a 
major component of the anti-alphaviral response, with mice triply deficient in Mx, PKR and RNase 
L showing no greater disease after alphavirus infection (268), although virus replication in 
lymphoid tissues draining infection sites was enhanced approximately ten-fold by the absence of 
PKR (268). Curiously, a nuclear ISG exonuclease, ISG20, was shown to significantly inhibit SINV 
replication, the mechanism of which is the subject of the current study (340). 
1.3.2 Interferon Induced Protein with Tetratricopeptide Repeat Family Proteins 
Following the discovery of the interferon, IFIT1 was one of the first effector proteins to be 
identified (368, 369). IFIT1 is now understood to be part of a family of proteins with related 
structural elements, including four known members in the human genome and three in mice (370-
377). IFIT family proteins are strongly induced by IFN-α/β and weakly induced by IFN-γ, and can 
be induced directly by alphavirus infection (339, 378). Most IFIT proteins contain 2 ISREs in the 
promoter, which are recognized by IRF9 in the ISGF3 complex, plus additional IRFs, including 
IRF3/7 (328, 370, 372, 375, 379). IFN-stimulation is not required for IFIT induction, however, 
leading to a distinction among ISGs as viral stress-inducible genes (380-382). IFIT1, the best 
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characterized family member in both humans and mice, is present at extremely low levels at rest 
in most tissues and is highly induced by IRF3 or the ISGF3 complex (383-386).  
IFIT proteins are not enzymatic in nature, and are instead thought to mediate protein-
protein and RNA-protein complex formation through their loosely conserved helix-turn-helix 
domains, termed tetratricopeptide repeats (387). Between human and mouse homologues of the 
conserved IFIT proteins, sequence similarity is rather degenerate, standing at about 50%, 
suggesting differences in activity and or mechanism between species (388). It is not surprising 
then that similar activities between mouse and human IFIT proteins are achieved through different 
mechanisms – involving separate species-specific protein interactions that ultimately lead to 
translation suppression (389). Among the known functions of IFIT proteins, translation 
suppression appears to be a primary conserved activity between species. In mice, this broad 
activity against host and viral translation is achieved by IFIT1 and IFIT2 independently binding to 
the eukaryotic initiation factor eIF3c, preventing ternary complex formation for cap-dependent 
translation (390, 391). This IFIT function has been shown to impede viral translation with HCV, 
with IFIT1 and IFIT2 localizing to replication sites with HCV RNA (392). Human IFIT1 has also 
been demonstrated to bind specifically to the E1 helicase of human papillomavirus (HPV), 
sequestering it to the cytoplasm and away from the nuclear replication factories where it functions 
(393). Relating to its translation-inhibitory functions, IFIT1 and IFIT2 in humans have also been 
shown to feedback negatively and suppress interferon signaling through STING and MAVS in 
most cell types by disrupting protein interactions in the IRF3 signaling cascade (394). 
In addition to its well-characterized protein binding activities, IFIT1 was most recently 
defined as an RNA binding protein, with specificity for 5’-triphosphate-RNA as well as type-0 2’-
O-unmethylated capped RNAs (395-397). Interestingly, the recognition of 5’-triphosphate RNA 
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by the IFIT proteins requires a minimum of IFIT1 and IFIT5 to function in humans, but only IFIT1 
in mice (395, 396, 398). The 5’-triphosphate binding activity of the human IFIT complex is 
sufficient to sequester VSV RNA in the cytosol, leading to reduced virus replication in culture and 
knockout mice (395, 397). The ability of IFIT1 to recognize type-0 cap structures is important for 
viruses that lack 2’-O-methylation of the 5’ terminal nucleotide associated with the 7-methyl-
guanosine cap, including the alphaviruses (3, 396). Indeed, the prototypical alphavirus, SINV, is 
significantly inhibited by IFIT1 overexpression in mouse cells (340). While this binding is 
significant, and leads to sequestration of type-0 capped RNAs in the cytosol, some alphaviruses, 
including VEEV, have evolved an evasion mechanism where the terminal nucleotide is bound in 
a terminal stem-loop, and thus inaccessible to IFIT1, which preferentially binds to ssRNA only (3, 
397, 398). Due to its alphavirus-associated RNA binding properties and translation inhibiting 
characteristics, IFIT1 is the focus of ongoing rational vaccine development and therapeutic 
approaches against multiple alphaviruses. 
1.3.3 20kDa Interferon Stimulated Gene, ISG20 
Based on previous results from our lab, the IFN-stimulated exonuclease, ISG20, is a potent 
inhibitor of alphavirus replication, and overexpression leads to a disproportionately high restriction 
of SINV replication in vitro (340). The ISG20/Isg20 gene codes for an approximately 20 kDa 3’-
5’ exonuclease in the DEDD family of nucleases related to the yeast Rex4 gene (399, 400). The 
ISG20 active site is composed of three acidic residues arranged in a catalytic triad, coordinating 
two Mn2+ ions at its core (400, 401). In vitro, ISG20 exhibits processive degradation kinetics on 
ssRNA substrates, and has reduced catalytic efficiency on ssDNA substrates (400). Double-
stranded regions, including hairpins, on both RNA and DNA substrates greatly reduce ISG20-
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mediated target degradation (400). The ISG20 protein consists of only a single catalytic domain, 
and lacks autonomous regulatory activity to guide substrate specificity or activation state (400, 
401). As such, the cellular or viral targets of ISG20 exonuclease activity are not well characterized, 
and may instead rely on additional cellular factors for recruitment or nonspecific binding. 
ISG20 is present at low resting levels in most cell types and is highly induced by both IFN-
α/β and IFN-γ, as well as by estrogen receptor signaling (399, 400, 402, 403). The ISG20 promoter 
is composed of an ISRE, which perfectly matches the ISGF3 consensus sequence, a gamma 
activation sequence, an NF-κB binding site, multiple GC stretches that are essential for strong 
promoter activity in the absence of a traditional TATA-box, and an E-box element that leads to 
USF-1-mediated constitutive low-level expression (402). The ISG20 ISRE is also minimally 
bound by IRF1, which alone is sufficient for transcription complex formation post-treatment with 
IFN-α/β (402, 403). 
ISG20 protein localizes primarily to the nucleus once induced, and is observed in tightly 
packed nucleolar puncta. This was originally designated as PML nuclear bodies, but later work 
identified these resident structures as Cajal bodies (CB) (399, 404). ISG20 binds in complex with 
both Coilin, the main structural component of CB, and SMN (404). In addition to these protein 
interactions, pull-downs associated with ISG20 revealed a complex with multiple snRNAs, U1, 
U2 and U3, known to localize to CB for post-transcriptional processing and assembly events (404). 
Whether these CB components are direct interaction partners for ISG20 or a consequence of its 
complex assembly is unclear. Interestingly, the primary protein sequence of ISG20 and solved 
crystal structure reveal no classical nuclear import signal, suggesting a role for an ISG20 binding 
partner in its nuclear import and retention (401).  
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1.3.3.1 ISG20 Antiviral Activity 
Since its discovery, ISG20 has been shown to directly inhibit the replication of viruses in the 
families Rhabdoviridae, Picornaviridae, Orthomyxoviridae, Retroviridae, Flaviviridae, 
Hepadnaviridae, and Togaviridae (339-342, 405-411). The antiviral activities of ISG20 were first 
demonstrated by Espert et al., highlighting a marked restriction of RNA virus replication with 
vesicular stomatitis virus (VSV), influenza virus (FLUAV) and encephalomyocarditis virus 
(EMCV), but not adenovirus, which possesses a DNA genome (405). Due to the previously 
demonstrated RNase properties of ISG20 and the observed restriction of antiviral activity to 
viruses with an RNA genome, a paradigm was established in which ISG20 was presumed to be 
directly targeting viral RNAs for degradation. Interestingly, work from this group also 
demonstrated for the first time that the ISG20 antiviral activity is dependent on a functional 
exonuclease, with a mutant of ISG20 exhibiting a dominant negative effect on the downstream 
effects of IFN against VSV infection (405). Of note, Espert et al. observed significant differences 
in the restriction phenotype between virus species, with EMCV and FLUAV demonstrating greater 
resistance to ISG20-mediated antiviral activity (405).  
A growing number of microarray and deep sequencing ISG functional studies have 
implicated ISG20 in the IFN-α/β-mediated restriction of several additional virus infections (339, 
342, 412-414). Overexpression in various cell culture and virus-based transgene models have 
highlighted the importance of ISG20 in controlling virus replication at the cellular and whole 
organism level. Expression of ISG20 from the human immunodeficiency virus-1 (HIV-1) genome 
robustly delayed HIV-1 reverse transcription and replication (406). However, prolonged exposure 
to ISG20 in this study resulted in escape mutations in the virus genome allowing uncontrolled 
replication (406). While mutation or deletion of the HIV-1-expressed ISG20 transgene would 
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result in the same escape phenotype, sequencing of the progeny virus indicated no change to the 
transgene or its promoter (406). This result is particularly significant, suggesting that ISG20 may 
inhibit virus replication through a mechanism other than non-specific degradation of viral RNAs.  
Our lab has previously reported a greater than two-fold increased survival rate in neonatal 
SINV challenge where Isg20 is expressed from a duplicate subgenomic promoter (340).  
Overexpression of ISG20 in murine embryonic fibroblasts led to a corresponding 100-fold 
reduction of SINV growth in vitro (340). A similarly robust in vitro antiviral phenotype was 
observed against hepatitis C virus (HCV), bovine viral diarrhea virus (BVDV), hepatitis A virus 
(HAV), yellow fever virus (YFV), West Nile virus (WNV), and dengue virus (DENV)  (342, 408, 
411). Interestingly, ISG20 overexpression did not restrict replication of the severe acute respiratory 
syndrome coronavirus (SARS-CoV), an RNA virus (411). Generally though, in studies where 
ISG20 was compared against similarly upregulated ISGs identified in target screens, ISG20 is 
consistently among the most potent at restricting viral replication and dissemination (340-342). 
While the potency of ISG20 antiviral activity against many RNA viruses is now well-
established, relatively little is known about its mechanism of action other than inferences derived 
from its exonuclease activity. For years, a model of ISG20-directed degradation of viral RNAs 
persisted (405). This paradigm was first challenged with the observation that HCV RNA is not 
degraded in the presence of overexpressed ISG20 (411). Furthermore, translation of HCV internal 
ribosomal entry site (IRES)-containing RNAs was not inhibited by ISG20 (411). Together, these 
observations suggest that the ISG20 exonuclease is acting on a substrate other than viral RNA for 
its inhibitory effect. The target of ISG20 exonuclease activity is not without controversy, however. 
Recent work by Leong et al. with hepatitis B virus (HBV) suggests that RNA intermediates 
produced during replication are a major target of ISG20 activity, with ISG20 accelerating the decay 
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of viral intermediates by approximately three-fold at three hours post-treatment with the 
transcription inhibitor, actinomycin D (410). While at odds with a model where ISG20 does not 
target viral RNA, this result may be a consequence of the HBV replication cycle where the partially 
ssDNA genome enters the nucleus and produces virally coded RNAs that serve as replication 
intermediates. This is in contrast to many other RNA viruses that replicate their genomes 
exclusively in the cytosol of infected cells. Another explanation for the discrepancy could be the 
treatment of cells with actinomycin D, which may disrupt ISG20 localization by dissociating CB 
(415, 416).  
In addition to the conflicting ISG20-mediated degradation mechanisms proposed, another 
recent study suggests that a catalytically functional ISG20 may directly inhibit translation through 
a steric hindrance mechanism (409). Qu et al. demonstrated that ISG20, but not an exonuclease-
deficient mutant, associates with FLUAV nucleoprotein during infection, resulting in a block of 
viral translation (409). It is not clear however whether this interaction is mediated by protein-
protein interactions, or facilitated through an RNA intermediate (409). While this work offers a 
potential alternative mechanism for ISG20-mediated virus restriction through altered translation 
kinetics, the predominantly cytoplasmic localization in these overexpression studies raises 
significant questions regarding the conclusions. This specific FLUAV nucleoprotein interaction 
also does not account for a more general translation-blocking mechanism for other virus species 
that do not have nucleoprotein-bound RNA genomes. 
1.3.3.2 Cajal Bodies 
The sub-nuclear localization of endogenous ISG20 to CB may offer some insight into its 
mechanism of antiviral activity. CB are complex structures of protein and RNA associated with 
dozens of individual proteins and guide RNAs plus target RNAs and complexed proteins (417). 
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These dynamic structures are highly mobile within the nucleus and can travel and associate with 
various genomic structures (416, 418). CB function is best understood for their role in recruiting 
and processing small-nuclear RNAs (snRNAs) of the spliceosome (415). Indeed, CB associate 
around the gene loci for snRNAs and small-nucleolar RNA (snoRNA) targets they post-
transcriptionally modify (419-422). The nucleation and mobilization of CB around their target loci 
is mediated by active Pol II transcription at these sites and requires unprocessed U2 snRNA (415, 
416, 423-425).  
Over the course of CB-associated maturation, snRNAs pass through the CB multiple times 
in order to complex with essential proteins and receive post-transcriptional modifications (426, 
427). Within the CB, snRNAs are methylated and pseudouridylated at specific residues, guided by 
the small CB-specific RNAs (scaRNAs), and are loaded in complex with spliceosomal proteins 
for maturation of the small nuclear ribonucleoprotein particles (snRNPs) (428, 429). In addition to 
final maturation and assembly of snRNPs, CB function as a non-essential catalyst for re-assembly 
of these complexes in transcriptionally active cells with rapid spliceosome turnover (430). In 
addition to their role in processing snRNAs, the CB is also essential for the processing of snoRNAs 
of the nucleolus, providing hypermethylation and trimming of the 3’-end (431, 432). Of note, CB 
function in the processing and final maturation of numerous snoRNAs lacking a 7-methyl-
guanosine cap structure (432-435). Recent evidence also suggests CB may play a role in 
telomerase RNA biogenesis in humans (436, 437). However this may not be a well-conserved 
function across species as mice lack this activity (438). 
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1.4 HYPOTHESIS 
The human alphaviruses are an important genus of RNA viruses with severe pandemic potential 
and risk of misuse as biological weapons. While the antiviral activities of IFN-α/β have been well 
documented for many alphaviruses, relatively little is known about the individual effectors that 
restrict replication and dissemination. Elucidating the molecular mechanisms of ISG antiviral 
activity is important for a general understanding of innate immune responses, and is particularly 
pertinent to the study of virus attenuation for rational vaccine design and identification of 
therapeutic targets. For example, understanding the mechanism of IFIT1 antiviral activity and viral 
evasion strategies has led to a novel approach to developing attenuated alphavirus vaccine 
candidates (data not shown). Similar attempts to probe antiviral mechanisms have been made with 
other ISGs with potent restrictive phenotypes (349-351, 355-359). 
Utilizing a systems biology approach, our lab previously sought to identify ISGs with 
antiviral activity against the canonical alphavirus, SINV (339). This screen yielded 44 genes of 
interest for follow-up study, and ultimately identified three proteins with highly restrictive 
phenotypes (339, 340). Two of these genes, IFIT1 and ZAP have been the subject of extensive 
mechanistic research. With regards to alphavirus infection, IFIT1, an RNA binding protein with 
the ability to bind type-0 capped RNAs, recognizes an exposed alphavirus 5’ cap and sequesters 
viral RNA away from translation machinery (3). ZAP, another RNA binding protein, acts as a 
binding platform to assemble a functional antiviral complex with hitherto unknown function (350, 
351). The third protein, ISG20, is a nuclear 3’-5’ exonuclease whose antiviral activity has been the 
subject of numerous studies with both RNA and DNA viruses.  
While it has been determined that the ISG20 exonuclease activity is essential for its 
antiviral effect, there is no clear understanding of how ISG20 suppresses viral replication. Work 
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from two groups using viruses with different replication strategies has indicated that ISG20 does 
and does not directly degrade viral RNAs (410, 411). Further confusing these data, ISG20 
primarily localizes to the sub-nuclear Cajal body, a fluid structure involved in the processing of 
numerous small RNAs and assembly of spliceosomes (404). As such, viral RNAs from genera that 
replicate solely in the cytosol, including the Alphaviruses, would likely not come in direct contact 
with ISG20 in the context of normal infection. Another mechanism has been proposed, suggesting 
ISG20 inhibits translation of viral proteins through protein-specific interaction with viral 
nucleoproteins (409). Such a mechanism, however, would not likely account for the broad antiviral 
activity of ISG20 observed against numerous virus families.  
Questions remain whether ISG20 exhibits uniform antiviral activity against human 
alphaviruses capable of causing significant disease, and how ISG20 achieves this antiviral activity. 
Herein, I describe our attempts to answer these questions and elucidate the antiviral activities of 
ISG20 in context of alphavirus infection with both WT and attenuated alphavirus strains in cell 
culture and in a recently-developed Isg20-deficient mouse model.  
• In Chapter 2, I hypothesize that ISG20 achieves its broad antiviral activity through an 
indirect mechanism, both dependent on its exonuclease function, and independent of direct 
viral RNA degradation in the cytoplasm. 
• In Chapter 3, I hypothesize that alphaviruses, particularly mutants sensitive to other 
effectors of the type I interferon system, are subject to reduced antiviral restriction in 
Isg20-/- mice compared to WT.  
The results of this study will elucidate potential mechanisms of ISG20 antiviral activity 
against alphaviruses, and demonstrate an approach for utilizing ISG20 for rational strategies of 
alphavirus attenuation and vaccine design. 
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2.1 INTRODUCTION 
Innate immune responses provide a first line of defense against many pathogens and act to 
stimulate adaptive immune responses, which in turn help to clear infections and generate a lasting 
immunological memory.  Stimuli from invading viruses trigger pathogen recognition receptors, 
which signal infected cells to produce early antiviral effectors and cytokines to alter gene 
regulation programs in neighboring cells. The most widely studied antiviral innate immune 
cytokine produced from this process, type I interferon (IFN), signals through its heterodimeric 
receptor (IFNAR1/IFNAR2) on infected and uninfected cells and activates the IFN-stimulated 
gene factor 3 complex (ISGF3) to transcribe a targeted set of interferon stimulated genes (ISG).  
These ISGs control a variety of antimicrobial functions by indirectly or directly limiting replication 
of the invading pathogen (439).  
Alphaviruses are small, single-stranded RNA viruses that are spread via the bite of an 
arthropod vector.  These include the arthritogenic Old World viruses such as chikungunya 
(CHIKV), Sindbis (SINV) and Ross River (RRV) viruses and the encephalitogenic New World 
2.0  ISG20 RESTRICTS ALPHAVIRUS REPLICATION IN VITRO THROUGH AN 
IRF3-DEPENDENT INDUCTION OF ANTIVIRAL FACTORS 
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viruses such as eastern (EEEV) and Venezuelan (VEEV) equine encephalitis viruses.  Together, 
these viruses include widespread emerging pathogens as well as one of the most acutely virulent 
RNA viruses known.  Several studies have revealed a role for individual IFN-α/β upregulated 
effector proteins in controlling alphavirus infection (3, 329, 339, 340, 354, 366, 440, 441). One 
contributor to the IFN-α/β antiviral response against alphaviruses that is particularly potent in vitro 
is the 20-kDa exonuclease, interferon stimulated gene 20 (ISG20) (340). ISG20 is a member of 
the RNA-specific DEXD family of 3’-5’ exonucleases and is localized predominantly in the dense, 
sub-nuclear structures of protein and RNA called Cajal bodies (399, 400, 404). ISG20 has been 
shown to restrict infection of multiple RNA and DNA viruses (340-342, 405-407, 409-411). Due 
to the capacity of ISG20 to degrade RNA nonspecifically in vitro and its limited effect on DNA 
viruses, it has been assumed that ISG20 targets viral RNA, resulting in degradation of the viral 
genome. However, this presumed activity has not been demonstrated in live cells where ISG20 
and viral RNA are largely confined to different subcellular locations. The alphavirus genome is 
replicated entirely in the cytoplasm of infected cells, and would not typically make contact with a 
nuclear-localized protein. 
Here, we describe the antiviral activity of murine ISG20 and its effect on alphavirus 
replication in an optimized murine cell culture system. Overexpression of ISG20 in fibroblasts 
potently restricted the replication of multiple alphaviruses through a block in viral translation 
before replication occurred, but, surprisingly, did not accelerate the degradation of viral RNA. 
However, the replication-blocking activity was dependent upon the presence of an intact ISG20 
exonuclease domain. In the absence of viral infection or IFN gene induction, overexpression of 
ISG20 but not a nuclease domain mutant, resulted in the induction of multiple genes, many of 
which have described or predicted antiviral activity. In this in vitro system, the induction of 
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antiviral genes was primarily dependent upon IRF3 transcription factor activity.  Notably, IFIT1 
was consistently among the genes most upregulated by ISG20 overexpression.  IFIT1 has been 
shown to play a prominent role in host cell recognition of non-self RNAs and suppression of viral 
mRNA translation (3). Notably, an IFIT1-sensitivie mutant of VEEV was significantly more 
susceptible to ISG20 overexpression activities in vitro. Together, the in vitro data provided herein 
suggests a role for ISG20 as an activator of IRF3 and regulator of steady-state antiviral activity 
against both arthritogenic and encephalitogenic alphaviruses. 
2.2 RESULTS 
2.2.1 Murine ISG20 Expression Potently Restricts Alphavirus Replication in vitro 
We first evaluated the antiviral activity of ISG20 against CHIKV and VEEV using a stable, 
inducible overexpression system. Two separately-derived clonal lines of tetracycline-inducible 
(tet-off) MEF cells overexpressing C-terminal FLAG-tagged murine ISG20, a homologous mutant 
of ISG20D94G (ExoII) shown in human ISG20 to disrupt the exonuclease activity through the Exo 
II domain (400), and enhanced green fluorescent protein (eGFP) or firefly luciferase (fLuc) as non-
antiviral controls (340) were generated. We confirmed overexpression of each protein by western 
blot against the FLAG epitope tag (Figure 4A).  Cellular localization of ISG20 was consistent 
with the published literature, forming dense nuclear puncta in confocal micrographs with 
additional diffuse cytoplasmic localization concentrated around the nuclear envelope (Figure 5A). 
To determine the magnitude of antiviral restriction by ISG20, tet-off cells were induced for 72 
hours and infected with WT CHIKV and VEEV, as well as an attenuated mutant, VEEV-G3A, 
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that possesses one of the mutations acquired by the VEEV TC83 vaccine strain during cell 
adaptation. This mutation alone confers decreased pathogenesis in mice due to a sensitivity to the 
IFIT1 antiviral effector (3). Overexpression of ISG20 reduced replication by approximately 100-
fold by 12 and 24 hours p.i. in both WT CHIKV- and VEEV-infected MEFs (Figure 4B-C). 
However, replication in the presence of the homologous ExoII mutant proceeded uninhibited, 
similar to eGFP control MEFs. Interestingly, replication of VEEV-G3A was restricted entirely at 
6 and 12 hours p.i. by ISG20 overexpression, and was still restricted over 1000-fold by 24 hours 
p.i. (Figure 4D). VEEV-G3A exhibited similar growth kinetics comparing the GFP control and 
catalytically inactive ISG20 ExoII overexpressing MEFs.  
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Figure 4: ISG20 Overexpression Restricts Wild-Type and Mutant Alphavirus Replication in vitro. 
(A) Two clones of tet-off MEFs expressing FLAG-tagged eGFP, murine ISG20, or the exonuclease 
domain mutant murine ISG20D94G (ExoII) were induced for 72 h then immunoblotted for FLAG-
tag to demonstrate inducible overexpression. Induced tet-off MEFs were infected with (B) WT 
CHIKV, (C) WT VEEV or (D) VEEV-G3A (MOI of 0.1). Replicated virus is measured from cell 
supernatants by BHK-21 plaque assay. * P < 0.05, ** P < 0.01, *** P < 0.001; 2-Way ANOVA 
with Holm-Sidak post-hoc analysis against eGFP control (n=6). 
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The CHIKV- or VEEV-TaV-GFP reporter viruses were used to determine whether ISG20 
restriction was a result of fewer cells initiating infection or a uniform reduction in replication 
efficiency. Fluorescent microscopy for eGFP revealed both a lower overall number of eGFP-
positive cells in both CHIKV and VEEV (Figure 5B-C). Again, the ExoII mutant did not exert an 
inhibitory effect compared to the fLuc control. 
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Figure 5: ISG20 Overexpression Reduces the Number of Productively Infected Cells. 
2.2.2 Exposure to CHIKV does not Change ISG20 Localization 
The nuclear localization of ISG20 has been demonstrated in the context of overexpression and IFN 
treatment of cells, but has not been demonstrated conclusively in the context of viral infection 
(404). Leong et al. recently published a putative function of ISG20 interacting with FLUAV 
nucleoprotein, leading to a block in viral translation (410). However, overexpressed ISG20 in their 
system favored cytoplasmic localization, contrary to the prior literature. Because alphaviruses 
replicate exclusively in the cytoplasm, it is necessary to determine whether ISG20 remains 
localized to nuclear puncta, or whether it redistributes in the context of viral infection, potentially 
associating with alphavirus proteins or RNA in the cytoplasm.  Induced MEFs overexpressing 
eGFP, ISG20 and ExoII were infected for 24 hours with CHIKV-TaV-mCherry and subjected to 
confocal microscopy for FLAG-tagged ISG20 and virus. ISG20 overexpressing cells did not show 
significant CHIKV reporter signal at 24 hours p.i. (Figure 6), similar to previous data with 
CHIKV-TaV-eGFP (Figure 5B). While these cells were exposed to CHIKV, ISG20 localization 
remained consistent (Figure 6). ExoII MEFs were efficiently infected and show a reduction in 
total non-viral gene expression as expected, with an observed overall reduction in ExoII expression 
rather than a specific change in localization from the nucleus to the cytoplasm (Figure 6).  
(A) Tet-off MEFs expressing murine ISG20-FLAG were grown on glass cover slips and induced 
for 72 h. ISG20 was detected by FITC-conjugate anti-FLAG (M1) monoclonal antibody and 
localization was determined by confocal microscopy. Images represent an averaged z-stack 
projection at 100x objective magnification. (B-C) Tet-off MEFs expressing the indicated protein 
were infected with CHIKV-TaV-eGFP or VEEV-TaV-eGFP fluorescent reporter virus (MOI of 1) 
and imaged by epifluorescence microscopy at 24 h.p.i. *** P < 0.001; 2-Way ANOVA with Holm-
Sidak post-hoc analysis against eGFP control (n=6) 
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Figure 6: ISG20 Nuclear Localization is not Altered by CHIKV Infection. 
2.2.3 ISG20 Overexpression Leads to a Block in Virus Genome Translation 
To narrow down the point of ISG20 intervention in the alphavirus replication cycle, we infected 
MEFs overexpressing either ISG20 or control proteins with CHIKV- and VEEV-nsP3-nLuc 
viruses. Reporter signal from these viruses requires translation of the nonstructural polyprotein, an 
event that requires translation of the full-length genome, and is not indicative of the later 
subgenomic RNA transcription and translation. The observed reduction of early CHIKV and 
VEEV non-structural reporter signal by 6-hours p.i. in the presence of ISG20 indicates a block in 
replication before the translation of the nonstructural polyprotein, one of the earliest stages in 
alphavirus replication following entry and capsid disassembly (Figure 7A-B). Interestingly, both 
CHIKV and VEEV appear to be similarly inhibited prior to nonstructural protein synthesis, 
indicating a broad action of ISG20 against members of the Alphavirus genus.  
MEFs overexpressing the indicated proteins were infected with CHIKV-TaV-mCherry subgenomic 
reporter virus (red) for 24 hours. Fixed cells were stained for C-terminal FLAG (green) tag and 
localization of ISG20 was determined by confocal microscopy.  
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Figure 7: Early Events in Alphavirus Replication are Inhibited by ISG20 Activity. 
Next, we tested whether ISG20 is capable of directly blocking the translation of incoming 
RNAs using reporters consisting of firefly luciferase flanked by the 5’ and 3’ non-translated 
regions from a host RNA, CHIKV or two unique internal ribosomal entry site (IRES) structures 
(Figure 8A) (125). This transfection-based approach removes the steps of binding and entry, 
allowing for a more direct visualization of initial viral macromolecular synthesis. Transfection of 
these constructs in MEFs overexpressing eGFP, ISG20 and ExoII revealed a marked decrease in 
the translation of the CHIKV-mimic reporter as well as the type-0 capped host-mimic reporter in 
the presence of ISG20 (Figure 8C). Notably, this effect was absent in the ExoII overexpressing 
cells, indicating that translation arrest is not an intrinsic characteristic of ISG20 overexpression, 
but is instead a specific activity of its functional exonuclease domain. IRES sequences can be 
utilized by some RNAs to initiate translation without the use of some or all components of the cap-
dependent translation machinery (442). The IRES from encephalomyocarditis virus (EMCV) 
Tet-off MEFs overexpressing the indicated protein were infected with (A) CHIKV-nsP3-nLuc or 
(B) VEEV-nsP3-nLuc non-structural reporter viruses at MOI=0.1 and lysates were collected at the 
indicated time points. Reporter signal is given as a ratio of relative intensity normalized to cellular 
protein. *** P < 0.001; (A-B) two-way ANOVA. (n=6) 
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requires all cap-dependent translation initiation factors to be present in order to initiate translation 
whereas the IRES used by cricket paralysis virus (CrPV) requires no additional host or viral factors 
to initiate translation (442). Transfected EMCV and CrPV IRES reporters were unaffected by 
ISG20, suggesting a targeted block in some cap-dependent translation rather than a global change 
in protein metabolism (Figure 8D-E). Furthermore, the ability of the EMCV IRES to escape 
translation arrest suggests that ISG20 is not triggering a broad block in cap-dependent translation 
through disruption of the eIF complex, but instead leads to a targeted recognition of alphavirus 
RNA elements used for translation initiation. Interestingly, these findings are similar to results 
obtained when evaluating the effects IFN-α/β treatment on virus reporter translation (128).   
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Figure 8: ISG20 Restricts Translation of Type-0 Capped, Non-IRES-Containing RNAs. 
(A) Schematic representation of type-0 capped and poly-adenylated non-replicating translation 
reporters. Luciferase gene is flanked by 5’ and 3’ non-translated regions for the indicated mRNA 
mimic. (B-E) Induced tet-off MEFs overexpressing the indicated protein were electroporated 
with 7.5 µg of indicated RNA then sampled at the peak of reporter signal, 3 hours. Relative 
luminescence is given as a percentage of signal at t0 (30 min post transfection). ** P < 0.01; (B-
E) two-way ANOVA. (n=12) 
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2.2.4 ISG20 Overexpression Does Not Accelerate Decay of the CHIKV RNA 3’-Terminus 
ISG20 was previously characterized as a 3’-5’ exoribonuclease capable of degrading non-specific 
RNA targets in a processive manner in vitro (400). Testing the effects of ISG20 overexpression on 
degradation of viral RNA requires introduction of RNA into the cell cytoplasm, in the context 
where RNA replication is inhibited such that only the introduced RNA is detected. Cycloheximide, 
a potent global inhibitor of translation, was shown to block translation of the CHIKV non-
structural polyprotein and sufficiently inhibit virus replication to decouple this effect (Figure 9A). 
Induced tet-off MEFs overexpressing ISG20, ExoII, or control eGFP, were then infected with WT 
CHIKV (MOI=5), and treated with cycloheximide in the inoculum and culture media. Primers for 
qRT-PCR were designed to target the 3’ terminus of CHIKV to detect the earliest signs of 3’-5’ 
degradation within the 3’ non-translated region, as would be expected from the characterized 
exonuclease activity of ISG20. qPCR analysis revealed a very gradual loss of CHIKV 3’-terminus 
signal over time in each of the tet-off MEFs, with no significantly acceleration in RNA decay from 
ISG20 overexpression (Figure 9B). Therefore, overexpression of ISG20 does not appear to 
accelerate the decay of viral RNA per its catalytic activity in vitro, suggesting an alternative 
pathway for translation suppression.  
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Figure 9: ISG20 Overexpression does not Accelerate Decay of CHIKV Viral RNA. 
Additionally, we examined whether virus RNA was functionally inhibited through 
irreversible modification, including degradation, by exposure to overexpressed ISG20 (Figure 
10).  In this case, non-replicating translation reporter RNA, which is highly repressed in ISG20 
expressing cells, was transfected into control or ISG20-expressing cells, harvested after 3 hours 
along with total cellular RNA and then re-transfected into control cells. RNA harvested from 
(A) MEFs were infected with CHIKV-nsP3-nLuc then treated with 0 or 10 µM cycloheximide to 
block translation, and ultimately replication, of CHIKV viral RNA. (B) MEFs were infected with 
WT CHIKV (La Réunion) then treated with 10 µM cycloheximide. RNA was collected at the 
indicated time p.i. and analyzed by qRT-PCR for the CHIKV 3’ terminus. RNA degradation is 
represented as a percentage of signal at t=0 hr. Not significant; (A-B) two-way ANOVA. (n=6) 
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control or ISG20-expressing cells exhibited similar translation activity after re-transfection, 
suggesting no functional differences (Figure 10B).  
 
Figure 10: Integrity of Non-replicating RNA is not Altered by Cellular Exposure to ISG20. 
(A) Schematic representation of the experimental workflow is shown. Tet-off MEFs 
overexpressing eGFP, ISG20, or ExoII mutant were transfected with 7µg of non-replicating 
CHIKV-mimic reporter RNA and RNA lysates were taken at 0 and 3 hours post electroporation. 
RNA was extracted and re-transfected in MEFs overexpressing either eGFP or ISG20 for 3 hours. 
Lysates were collected in passive lysis buffer and assayed for firefly luciferase reporter activity. 
(B) Luciferase activity from second transfections is given as a ratio of firefly luciferase signal from 
3 hour versus 0 hour samples taken from first transfection. Not significant; (B) Mann-Whitney test. 
(n=6) 
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2.2.5 ISG20 Overexpression Regulates a Focused Gene Expression Response 
Previously, we identified an effect of IFN on virus genomic translation mediated by gene 
upregulation after IFN-α/β treatment associated with production of multiple antiviral gene 
products (128, 339).  Since alphavirus replication and translation reporter activity were both 
strongly inhibited by ISG20 in the absence of effects on RNA stability, resembling IFN-α/β 
treatment, we used a transcriptomics approach to determine if the regulation of other antiviral or 
IFN-induced genes was altered in the ISG20 overexpressing cells.  
RNA deep sequencing (RNA-seq) of MEFs overexpressing ISG20 in the absence of 
infection revealed a unique pattern of gene regulation that was independent of IFN stimulation. 
The most highly upregulated genes, which exhibited a five-fold or greater induction compared to 
both control and ExoII mutant cells, tended to have known antiviral activity or were known to be 
inducible by type I or II IFN (Figure 11A). No IFN-α/β, IFN-γ or IFN-λ genes were significantly 
upregulated by ISG20 overexpression as determined by RNA-seq and qRT-PCR. Among the top 
gene targets identified were several IFN-inducible proteins with tetratricopeptide repeats (IFIT 
family) including Ifit1 and Ifit3, as well as multiple IFIT-like genes (Figure 11B). Interestingly, 
not all IFIT family proteins were upregulated, with Ifit2 standing out as an ISG that was not 
affected by ISG20 overexpression. Additionally, several complete gene families such as the 
ubiquitin-like Isg15, the ISG15 E3-ligase, Herc6, and the de-ISGylating Usp18 were induced 
(Figure 11B).  Upregulated genes also of note were multiple IRF and STAT genes, and the viral 
RNA-sensing helicase Ddx58 (RIG-I). Network analysis of ISG20 overexpression highlighted a 
pattern similar to that of viral infection or IFN response without the primary signaling components 
of type I, II or III IFN or their receptors being induced (Figure 11A). In addition to IFN-like 
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responses, eIF2 signaling, eIF4 signaling and mTOR signaling were increased in response to 
ISG20 in the cell culture system (Figure 11A).  
 
Figure 11: ISG20 Overexpression in the Absence of Infection Results in Targeted Gene Upregulation. 
RNA-seq was performed on MEFs expressing eGFP and ISG20. (A) Differential gene expression 
was analyzed and upregulated canonical pathways are shown. (B) A heat map of the most 
significant ISG20-induced genes is shown. Temperature ranges are shown as fragments per 
kilobase of transcript per million mapped reads (FPKM) from green (low) to red (high). P < 0.001; 
Cuffdiff 2 gene expression model, FDR = 5%. (n=2) 
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Upregulation of the most significantly induced set of genes from RNA-seq were independently 
confirmed by qRT-PCR (Figure 12A). Ifit1, was consistently upregulated approximately ten-fold 
over basal levels in ISG20 overexpressing cells (Figure 12A).  This upregulation in mRNA levels 
led to increased protein expression that was specific to a functional ISG20 protein (Figure 12B-
C).  
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Figure 12: Overexpression of ISG20 Upregulates Antiviral Factors in vitro. 
Tet-off MEFs expressing eGFP, ISG20, or ExoII mutant were induced for 72 h, and total cellular 
RNA and protein were collected. (A) A selection of genes identified to be induced by ISG20 
overexpression through RNA-sequencing were confirmed by qRT-PCR or (B) IFIT1 protein 
induction was confirmed by western blot for two independent clones of each overexpressing cell 
line and quantified in (C). (A,C) * P < 0.05, ** P < 0.01; Mann-Whitney test. (n=6) 
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2.2.6 ISG20-mediated Gene Induction Profile Involves IRF3 
Interestingly, many of the genes unregulated by ISG20 are also upregulated by IRF3 activation 
(383). Indeed, our pathway analysis of the ISG20-regulated genes implicates IRF3 as a candidate 
for regulating the ISG20 response (Table 4). To elucidate the role of IRF3 activity in mediating 
ISG20 induction of ISGs, we transfected luciferase plasmids containing the complete IFN-β 
promoter or its constituent two IRF3-binding elements and one NF-κB-binding element 
individually into our overexpression MEFs. ISG20 overexpression leads to an increase in 
luciferase expression in cells transfected with the entire IFN-β promoter as well as cells transfected 
with the partial promoter containing only the two IRF3 components (Figure 13A). Notably, the 
NF-κB element alone was insufficient to significantly drive ISG20-stimulated promoter activity 
(Figure 13A), consistent with previous findings that NF-κB is a poor stimulator of the IFN-β 
promoter on its own (443). The stimulation of these promoters in the presence of ISG20 
overexpression alone was similar to cells treated with lipid-transfected poly-(I:C) (Figure 13A). 
Expression of the exonuclease-deficient ExoII mutant did not drive promoter activity of the 
complete IFN-β promoter or its constituent elements, and responded poorly to poly-(I:C) 
treatment, consistent with previous reports describing a dominant negative effect of ExoII on the 
antiviral activities of IFN (Figure 13A) (405). Furthermore, siRNA knockdown of IRF3 in tet-off 
MEFs overexpressing ISG20 revealed a significant reduction in ISG20-modulated gene 
upregulation versus a non-targeting control for multiple gene targets (Figure 13B). Together, these 
findings indicate that IRF3 is largely responsible for the transcription profile observed with ISG20 
overexpression. Despite apparent upregulation of IRF3-responsive genes, IFN genes were not 
among the transcripts upregulated by ISG20 overexpression (Table 2). To confirm this, we 
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assessed functional type I IFN production in induced tet-off MEFs in the presence or absence of 
poly-(I:C) lipid transfection. ISG20 induction alone was not sufficient to produce secreted IFN, 
though all MEFs produced similar levels of IFN in response to the TLR3 agonist, poly-(I:C) 
(Figure 13C). 
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Figure 13: ISG20 Regulates Targeted Gene Expression through IRF3 Activation. 
(A) MEFs expressing eGFP or ISG20 were induced and transfected with luciferase driven by IFN-β 
promoter (pβLUX), or the IRF3 responsive elements (PRDI/III) and NF-κB element of the IFN-β 
promoter (PRDII). Induction is given as a ratio of firefly luciferase expression to SV-40 promoter-
driven Renilla luciferase. (B) MEFs expressing GFP, ISG20 and ExoII mutant were induced and 
treated at 24 h with siIRF3 or siRNA scramble for an additional 48 h. Selected genes were assessed 
by qRT-PCR and induction levels are given as fold-change from scram-treated GFP control. (C) IFN 
was measured in the tet-off MEF cell culture supernatant before and after poly-(I:C) lipid 
transfection. * P < 0.05, ** P < 0.01, *** P < 0.001; (A,C) ANOVA with Dunnett post-hoc analysis 
(n=6), (B) Mann-Whitney test (n=6). 
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2.3 DISCUSSION 
Type I IFN-stimulated genes play multiple roles in detecting and suppressing virus replication. 
Over 300 gene products can be induced by type I IFN, creating a restrictive environment that may 
have both general and specific viral- and microbial-family targets. The activity of numerous ISGs 
has now been elucidated through extensive study of the molecular basis of target restriction, but 
the antiviral activity of many continues to remain elusive. ISG20 was first biochemically 
characterized as an IRF1-induced gene with high homology to DEDD-domain nucleases in the 
same family as the S. cerevisiae rex4p gene (400, 402). An activity of ISG20 demonstrated in vitro 
was non-specific degradation of single-stranded nucleic acid substrates with a preference for 
ssRNA, showing a 3’-5’ exonuclease activity (400).  
Antiviral activity for ISG20 in cells has been shown through overexpression for a number 
of RNA viruses (340-342, 405-407, 409-411), including the prototypical alphavirus, SINV (340). 
However, these studies did not define the mechanism of ISG20 restriction on RNA virus 
replication in cells or animals. In the present study, we sought to establish a model system for 
determining the molecular basis of the restriction by ISG20. Stable overexpression of the dominant 
murine ISG20 (isoform b), which bears 82% homology to human ISG20, had a significant 
restrictive influence on CHIKV, VEEV, and VEEV-G3A replication in vitro, consistent with 
earlier findings with SINV (340). Introduction of a homologous glycine mutation at the catalytic 
aspartic acid D94 in the ExoII exonuclease domain was sufficient to abrogate the antiviral activity 
of ISG20 in vitro, consistent with the published role of ISG20 catalytic activity on its antiviral 
function.  
Recent reports have suggested that ISG20 may be directly involved in viral RNA 
degradation, accounting for its observed antiviral activities. Findings with hepatitis B virus suggest 
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that ISG20 restricts viral replication through a direct degradation of viral RNAs and genomic 
intermediates produced over the course of infection (410, 444). In our cell culture model, the 
extreme 3’ terminus of the CHIKV genome was protected from ISG20-mediated degradation and 
was further shown to be translation competent following ISG20 exposure in cells, consistent with 
results obtained with IFN treatment, which induces ISG20 among other cellular nucleases (128). 
Unlike hepatitis B virus, the alphavirus RNA genome is replicated entirely in the cytoplasm, and 
would not be potentially exposed to the nuclear puncta containing ISG20. Thus our results more 
closely mimic previous work demonstrating that RNA from hepatitis C virus, a cytoplasmically-
replicating virus, is not degraded by ISG20 during the course of infection (411).  
Another study attempting to demonstrate the in vitro antiviral activity of ISG20 using 
influenza A virus suggested that ISG20 directly interacts with viral RNA to block translation, 
specifically binding to the influenza nucleoprotein to facilitate this activity (409). One caveat to 
these experiments however is the abnormal distribution of ISG20 observed in their transient 
overexpression system, favoring an atypical cytoplasmic localization, even in the absence of 
influenza nucleoprotein. In our in vitro model, we observed the punctate, primarily-nuclear 
localization of ISG20 consistent with previous studies (404). We too observed an ISG20-specific 
restriction of virus translation, but only in our host- and CHIKV-mimicking, type-0 capped RNAs, 
consistent with previous findings demonstrating that translation from the HCV IRES is unaffected 
by ISG20 overexpression (411). Restriction was not observed for reporters containing an internal 
ribosomal entry site from encephalomyocarditis virus (EMCV) or cricket paralysis virus (CrPV), 
indicating the block in translation is the result of a cap-dependent mechanism, and not a more 
general reduction in protein synthesis or RNA degradation. Despite the localization inconsistencies 
between studies, it is possible that ISG20 may employ multiple mechanisms of translation 
 69 
restriction dependent upon the virus. In light of recent work with hepatitis B virus demonstrating 
ISG20 accumulation on particular secondary structures within viral RNAs, ISG20 may in fact 
contribute to the restriction of nuclear replicating RNA viruses through direct binding or 
degradation (444). However, the catalytically-inactive ExoII was still capable of binding HBV 
RNA (444). ExoII did not arrest translation of the alphavirus reporters, suggesting direct RNA-
binding by ISG20 is not the primary mechanism of alphavirus translation suppression. 
The localization of ISG20 may offer some additional insight as to its mechanism of 
antiviral action. Despite being a small, soluble protein capable of free diffusion through the nuclear 
pore complex, ISG20 localizes primarily in the nucleus and interacts with the protein- and RNA-
rich Cajal bodies (404). The primary purpose of these structures is the processing and modification 
of small nuclear RNAs that make up the spliceosome (445, 446), suggesting that ISG20 may 
influence virus replication through the regulation of additional antiviral effectors rather than 
directly degrading viral nucleic acids. Our transcriptional analysis of ISG20 overexpressing MEFs 
revealed more than 100 genes significantly regulated by the ISG20 exonuclease, including two 
interferon regulatory factors (IRFs), the cytoplasmic viral RNA-detecting helicase RIG-I (Ddx58), 
and members of the interferon-induced protein with tetratricopeptide repeats (IFIT)-family. Ifit1 
upregulation stands out in particular because it has been previously characterized to inhibit 
translation of type-0 capped RNA in a manner consistent with our findings with ISG20 
overexpression.  
Our upstream pathway analysis of ISG20-mediated gene regulation strongly implicates the 
involvement of one or more IRFs in the transcriptional cascade observed following Isf20 
overexpression. IRF3 – one such candidate – is a master regulator of both primary IFN-β 
production and is directly responsible for the induction of multiple virus-stimulated genes (VSGs), 
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which do not require IFN for transcription (383). IRF3 transcriptional activity on the promoters of 
IFN-β and VSGs is activated through the recognition of PAMPs in the cytosol and endosomes, 
ultimately leading to the activation of IRF3 and transcriptional regulation of ISRE-like sequence 
in target promoters. Our genetic results suggest that the ISG20-mediated antiviral response is 
facilitated by IRF3 transcriptional activity. Thus, the involvement of IRF3 presents a potential 
mechanism for ISG20-directed gene transcription, where a potential degradation product of ISG20 
catalytic activity is serving to activate the transcriptional activities of IRF3 and perhaps its 
downstream effectors including IRF7 and IRF9. While the involvement of IFN production does 
not appear to play a role in ISG20-mediated transcription responses in our cell culture system, this 
pathway would suggest that ISG20 may also serve as a positive feedback mechanism in the 
production of IFNs, which may be produced below the limit of detection in our current assays or 
play a greater functional role as a feedback regulator in vivo. 
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3.1 INTRODUCTION 
Antiviral effectors of the IFN-α/β response play a crucial role in the pathogenic outcomes of 
alphavirus infections in mouse models of disease. Mice lacking signaling components of the IFN-
α/β cascade, including STAT1 and the IFN-α/β receptor (IFNAR), succumb to fatal systemic 
disease from both the arthritogenic and encephalitogenic alphaviruses (127, 167, 169, 344). While 
numerous ISGs induced by this response have demonstrated anti-alphaviral activity in cell culture 
models of infection, relatively little work has been done to recapitulate these findings in animal 
models of disease.  
In vitro models for ISG activity often rely on overexpression and RNA-interference 
knockdown of a single antiviral effector, which may or may not properly represent the 
physiological expression conditions following IFN-stimulation and ISG induction. Furthermore, 
several ISGs may act with binding partners that are not concurrently upregulated in single-ISG 
overexpression studies. While informative on their own, these studies are best complimented by 
evaluating the effects of individual ISGs in animal models of disease to define a physiologically 
3.0  ISG20 PROTECTS FROM IFIT1-SENSITIVE VIRUS CHALLENGE IN VIVO, 
BUT NOT WT ALPHAVIRUS INFECTION 
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relevant role for ISG activity in vivo. Homozygous knockout mice have been used to study the role 
of IFIT1 and ISG15 restriction of VEEV and CHIKV respectively, elucidating functional activity 
for both in the context of innate immune restriction of viral pathogenesis (3, 354). 
Study of ISG20 in vivo has previously been restricted to tissue specific overexpression or 
knockdown through hydrodynamic injection of constitutive-expression plasmids or short hairpin 
RNA (shRNA) (340-342, 405, 406, 409-411, 444). Utilizing Ifnar1-/- mice, the authors of one 
study demonstrated that tissue-specific expression of ISG20 in the absence of other IFN-α/β 
effectors is sufficient to reduce HBV viral load (410). Subsequently, RNAi knockdown of Isg20 
in WT mouse livers resulted in a concurrent increase in HBV viral load (410). This study, however, 
does not demonstrate the systemic influence of ISG20, and importantly misses potential regulatory 
activity associated with ISG20 as a positive feedback mechanism for IFN production.  
In the present study, we describe for the first time an Isg20-/- mouse model for the study of 
viral infection. Utilizing a combination of WT CHIKV, VEEV and EEEV and IFIT1-sensitive, 
attenuated strains of VEEV and EEEV (VEEV-G3A and EEEV-nt4&6), we demonstrate the 
fundamental importance of ISG20 for a functional innate immune response to alphavirus infection. 
Our findings indicate a minimal individual contribution by ISG20 in protecting against sub-lethal 
CHIKV challenge in adult mice, and lethal challenge of neonates. Furthermore, ISG20 does not 
significantly influence disease course and average survival time for adult mouse models of WT 
VEEV and EEEV infection. However, Isg20-/- mice infected with WT VEEV present neurological 
symptoms sooner than their WT counterparts. VEEV-G3A and EEEV-nt4&6 are uniformly lethal 
in Isg20-/- mice with <100% mortality observed for both viruses in WT mice. Further 
characterization of VEEV-G3A pathogenesis in Isg20-/- mice revealed a consistent increase in 
early viral load in both draining lymph nodes and serum, concomitant with reduced early serum 
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IFN production. Likewise, primary fibroblasts and osteoblasts isolated from Isg20-/- mice 
demonstrate an increased susceptibility to VEEV-G3A infection, regardless of IFN-priming. 
Together, our results demonstrate that ISG20 critically restricts IFIT1-sensitive, but not WT, 
alphaviruses in vivo, and support a role for ISG20 as a feedback regulator of IFN-α/β and VSG 
production in response to viral infection. 
3.2 RESULTS 
3.2.1 ISG20 Does Not Protect Against WT Alphavirus Challenge in Mice  
With the robust in vitro restriction observed with ISG20 overexpression, we sought to verify our 
findings in a small animal model of CHIKV infection. Utilizing an adult mouse model for CHIKV 
musculoskeletal disease (168, 345, 447), 3-week old male mice were infected with 103 PFU WT 
CHIKV (La Réunion) subcutaneously in the left rear footpad and disease was tracked by arthritis 
manifested as swelling in the infected and contralateral, un-infected footpad. We observed no gross 
pathological differences in footpad swelling between Isg20-/- and B6 mice in response to CHIKV 
infection (Figure 14A). Furthermore, serum, inoculated footpad and popliteal lymph nodes 
draining the infection site were collected and the level of CHIKV genomic RNA was assessed by 
qRT-PCR. No significant differences in RNA levels detected between all tissues harvested from 
Isg20-/- and B6 mice (Figure 14B) were observed.  In addition, no detectible serum IFN-α/β was 
detectible in infected animals at 24 hours p.i. 
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Figure 14: ISG20 does not Protect from CHIKV Disease in Adult Mice. 
In addition to the non-lethal adult model of CHIKV infection, neonatal pups lacking a fully 
developed immune system may be used to assess pathogenic differences of CHIKV between 
mouse strains through differences in survival time due to an underdeveloped type I interferon 
response, potentially allowing the effects of a single missing ISG to manifest (167, 448). 
Homogenized litters of Isg20-/- and B6 pups were infected with 103 PFU CHIKV subcutaneously 
in the axial region and housed with a surrogate mother.  
3-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU WT 
CHIKV (La Réunion) in the left hindlimb footpad. (A) Swelling was determined by footpad cross-
sectional area measured as an ellipse at 24-hour intervals for 3-weeks p.i. (B) CHIKV genomic 
RNA was measured by strand-specific qPCR at 24-hours post infection in serum, footpad, and 
popliteal lymph node draining infection. Not significant; (A) two-way ANOVA (B) Mann-Whitney 
test.  
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Neonates succumbing to disease earlier than 6-days p.i. manifested symptoms indicative 
of a systemic inflammatory response syndrome-like disease as is observed with Sindbis virus 
(449). However, after 6 days, neurological symptoms developed in all surviving mice, consisting 
of severe ataxia progressing to hind limb paralysis. No differences in median survival times or 
disease manifestations were observed between Isg20-/- and B6 neonates infected with CHIKV, 8.0 
+/- 3.7 days and 8.5 +/- 2.1 days respectively (Figure 15A-B). Indeed, survival correlated more 
closely with birth weight than mouse strain across groups (data not shown).  These findings 
indicate that while CHIKV is greatly modulated by ISG20 overexpression in vitro, CHIKV 
restriction in mice does not appear to be prominently influenced by the presence of a functional 
ISG20 exonuclease.  
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Figure 15: ISG20 is not Protective Against Fatal CHIKV Challenge in Neonatal Mice. 
Non-fatal disease could be a confounding factor in determining small effects contributed 
by ISG20. The encephalitigenic alphaviruses, VEEV and EEEV, cause uniformly fatal disease in 
adult mice, and differences in virulence can be assessed quantitatively through survival and scoring 
of clinical manifestations. Age matched, adult male mice were infected subcutaneously with 103 
PFU of either VEEV WT (ZPC738) or EEEV WT (FL93939) in both rear footpads and morbidity 
and mortality were monitored.  
1-day old neonatal mice were infected subcutaneously in the axial region with 103 PFU CHIKV 
WT and monitored for (A) weight loss and (B) survival. Not significant; (B) log-rank test. 
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VEEV WT-infected Isg20-/- mice demonstrated earlier onset of symptoms, while clinical 
manifestations in B6 mice consistently followed about 24 hours later (Figure 16C-D and Figure 
18A). However, no differences in median survival times were observed for mice infected with 
VEEV WT, with 5.50 +/- 0 days and 5.75 +/- 0.25 days for B6 and Isg20-/- mice respectively 
(Figure 16B). EEEV WT infected mice demonstrated no significant differences in either clinical 
disease score or median survival time, with animals succumbing to disease by 5.0 +/- 0.5 days and 
6.5 +/- 0.7 days for WT and Isg20-/- mice respectively (Figure 17A-D). With expanded clinical 
scoring of behavioral changes, VEEV WT infected Isg20-/- mice rapidly progress to a level of 
jumpiness and responsiveness to external stimuli unseen in their WT counterparts, suggestive of 
changes in visual acuity in these animals (Figure 18A). However, no such differences are observed 
in EEEV WT infected mice (Figure 18B). 
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Figure 16: ISG20 is not Protective Against WT VEEV Challenge. 
6-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU VEEV 
WT (ZPC738) in each hindlimb footpad and monitored for (A) weight loss, (B) survival and (C-D) 
clinical disease score. Not significant; (B) log-rank test. (n=4) 
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Figure 17: ISG20 is not Protective Against WT EEEV Challenge.  
 
Figure 18: ISG20 Delays WT VEEV Disease Onset.  
 
6-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU EEEV 
WT in each hindlimb footpad and monitored for (A) weight loss, (B) survival and (C-D) clinical 
disease score. Not significant; (B) log-rank test. (n=3) 
Expanded clinical scoring criteria are given for (A) VEEV WT- and (B) EEEV WT-infected mice 
with specific behavioral changes noted. (n=3-4) 
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3.2.2 ISG20 Protects Against IFIT1-sensitive Alphaviruses in Mice 
Collectively, our in vitro overexpression findings suggest a role for ISG20 as a regulator for 
inducing ISGs as part of the antiviral response. Ifit1 was highly upregulated by ISG20 
overexpression and functions by restricting virus translation. VEEV is an encephalitogenic 
alphavirus with a well-characterized resistance mechanism to IFIT1 translation restriction present 
in WT strains (3). A single nucleotide mutation derived from the VEEV TC83 vaccine strain, G3A, 
disrupts the terminal stem loop structure and reveals a 3-nucleotide overhang for IFIT1 detection 
of the type-0 alphavirus RNA cap structure (3). Given the enhanced sensitivity of VEEV-G3A to 
ISG20 overexpression in vitro, we explored the impact of IFIT1-sensitivity in Isg20-/- mice.  
Mice infected with VEEV-G3A displayed similar early differences in disease clinical 
score, with Isg20-/- mice succumbing to neurological symptoms sooner than B6 (Figure 19C-D). 
Similarly, severe neurological deficits were observed with VEEV-G3A infection in Isg20-/- mice 
as with VEEV WT (Figure 19D). Interestingly, most B6 mice also demonstrated behavioral 
abnormalities by 6-days post infection, including hunched posture and ataxia, but about 50% 
recovered fully by 11-days p.i., with no observed lasting neurological deficits (Figure 19C). 
Additionally, Isg20-/- mice experienced more rapid weight loss than B6 between replicate 
experiments (Figure 19A). Isg20-/- mice uniformly succumbed to VEEV disease, while 50% of 
B6 animals fell ill, but eventually recovered by 12 days p.i. Median survival time for VEEV-G3A 
was 11.0 +/- 0.5 days and 7.0 +/- 1.4 days in B6 and Isg20-/- mice respectively (Figure 19B). 
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Figure 19: ISG20 Protects from VEEV-G3A Infection.  
The single G3A point mutation in the VEEV 5’-NTR shifts the terminal stem loop 
positioning, conferring a 3-nucleotide terminal overhang – enough for type-0 cap detection and 
binding by IFIT1 (3). Using a similar approach, our lab developed a double point mutant, EEEV-
G4A/G6A (EEEV-nt4&6), which is similarly predicted to reduce steric hindrance from the 5’-
terminal stem loop and exposes the cap structure to IFIT1 (Figure 20A-B) (Trobaugh et al., 
unpublished manuscript). Both B6 and Isg20-/- mice infected with EEEV-nt4&6 experienced an 
approximately 3-day delay in disease onset compared to EEEV WT infection (Figures 17, 21). 
While EEEV WT is rapidly lethal following the onset of symptoms, EEEV-nt4&6 manifests with 
a brief prodromal phase followed by progressive neurological deficits (Figure 21C-D). No 
differences were observed between B6 and Isg20-/- mice in the onset of disease as measured by 
6-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU VEEV-
G3A in each hindlimb footpad and monitored for (A) weight loss, (B) survival and (C-D) clinical 
disease score. ** P < 0.01; (B) log-rank test. (n=6-7) 
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weight loss (Figure 21A) or disease scoring (Figure 21C-D). However, Isg20-/- mice more rapidly 
progressed with EEEV-nt4&6 neurological involvement, with all mice severely ataxic by 9 days 
p.i. (Figure 21C-D). EEEV-nt4&6 was uniformly lethal in Isg20-/- mice, while 16% of B6 animals 
survived challenge with no disease (Figure 21B). Median survival times for B6 and Isg20-/- mice 
were 11.0 +/- 1.1 days and 10.0 +/- 0.6 days respectively. 
 
Figure 20: EEEV and EEEV-nt4&6 5'-NTR Fold Predictions 
Predicted 5’-terminal stem-loop folds were calculated by mfold (v.2.3 energies). Stem-loop and 
terminal nucleotide overhangs are shown for (A) WT EEEV and (B) EEEV-nt4&6 with 
corresponding Gibbs free energy predictions at 37ºC and physiological conditions. 
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Figure 21: ISG20 Protects from EEEV nt 4&6 Challenge.  
Events within the first 24 hours of infection can act as critical determinants of disease 
outcome as the induction of the type I IFN response slows the spread of disease and helps to prime 
the adaptive immune response. Thus, VEEV-G3A virus growth was measured at 12 and 24 hours 
p.i. to determine the extent of virus replication and spread in key tissues and again at five days 
when neurological symptoms typically appear. At 12 hours p.i., we detected a five-fold increase 
in serum IFN-α/β levels in B6 mice compared to Isg20-/- (P < 0.01, Figure 22E).  However, serum 
IFN levels in Isg20-/- mice increased to similar levels as seen in B6 mice by 24 hours p.i. (Figure 
22E). Replication in the draining popliteal lymph node (PLN) was found to be significantly 
elevated in Isg20-/- mice compared to B6 mice (P < 0.01, Figure 22A) at 12 hours p.i. Interestingly, 
6-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU EEEV-
nt4&6 in each hindlimb footpad and monitored for (A) weight loss, (B) survival and (C-D) clinical 
disease score. ** P < 0.01; (B) log-rank test. (n=6) 
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50% of the B6 mice at 12 hours p.i. did not exhibit detectable lymph node replication (Figure 
22A); although serum titers were similar between the all mice at this time (Figure 22C). By 24 
hours p.i., all B6 mice had virus replication in their PLN at which time serum titer was elevated 
approximately two-fold in Isg20-/- mice (P < 0.05, Figure 22C). By 5 days p.i., VEEV-G3A was 
undetectable in serum, popliteal lymph node and the spleen in both B6 and Isg20-/- mice (Figure 
22A-C). Virus was detectible at greater than 105 PFU in the brain at five days p.i. in both B6 and 
Isg20-/- mice, with the latter reproducibly but not significantly higher (Figure 22D). No other 
significant differences in virus replication were detected in the spleen or the brain at any time point 
examined. IFN-β mRNA levels were consistently lower in popliteal lymph node and spleen of 
Isg20-/- mice infected with VEEV-G3A, with significantly fewer IFN-β transcripts at five days p.i. 
in the spleen (Figure 22F-G). IFN-β transcript levels in the brain remained consistent between B6 
and Isg20-/- mice across all time points tested (Figure 22H). 
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Figure 22: ISG20 Enhances IFN Production and Limits Replication of VEEV-G3A in vivo.  
6-week old male C57Bl/6J and Isg20-/- mice were inoculated subcutaneously with 103 PFU VEEV-
G3A in each hindlimb footpad and tissues or serum were harvested for RNA or live virus extraction 
at 12 hours, 24 hours, or 5 days p.i. Virus titers were determined for (A) popliteal lymph nodes, (B) 
spleen, (C) serum, and (D) Brain. (E) Serum IFN and local IFN-β transcription was determined for 
(F) popliteal lymph node, (G) spleen, and (H) brain at each time point. * P < 0.05, ** P < 0.01; (A-
E) multiple t tests, (F-H) Mann-Whitney test. (n=4) 
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3.2.3 Isg20-/- Primary Cells are more Susceptible to CHIKV and VEEV Infection 
The differences observed in mouse tissue replication suggest that ISG20 may be playing a role in 
the innate responses of particular cell types, which may influence the overall outcome of infection 
with IFIT1-sensitive viruses. We first assessed Isg20 induction in response to both IFN treatment 
and virus infection. Both CHIKV infection and IFN treatment significantly induced Isg20 in 
primary MEFs, but Isg20 was only induced by IFN in osteoblasts, at reduced levels (Figure 23A).  
In order to determine cell-specific effects of Isg20-deficiency, primary cells were generated 
from sex- and age-matched B6 and Isg20-/- mice. Primary MEFs and osteoblasts were infected 
with CHIKV-LR or VEEV-G3A to measure virus replication in these early primary cell targets of 
virus infection ex vivo (125, 450). In the absence of type I IFN priming, CHIKV replicated to 
approximately ten-fold higher levels by 24 hours in Isg20-/- MEFs compared to B6 MEFs (P < 
0.01, Figure 23B). When MEFs were primed with 10 and 100 IU of IFN-α4/β at a 1:1 ratio for 4 
hours, we observed a similar difference in virus replication, with approximately ten-fold greater 
replication in Isg20-/- MEFs over B6. In osteoblasts, a minor increase in CHIKV virus replication 
was seen in Isg20-/- cells compared to B6 in the absence of IFN priming (Figure 23C). However, 
this difference was not statistically significant. Following IFN priming, CHIKV replicated to 
similar levels in both Isg20-/- and B6 osteoblasts demonstrating cell-specific differences in ISG20 
antiviral effects (Figure 23C).  
Similar results were seen in MEFs infected with VEEV-G3A. In Isg20-/- MEFs, a 100-
10,000-fold increase in VEEV-G3A replication was measured compared to B6 MEFs (P < 0.01, 
Figure 23D). These differences were maintained in the presence of IFN treatment, where B6 MEFs 
released no detectible virus at 24 hours p.i. (Figure 23D). VEEV-G3A also experienced significant 
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gains in replication in primary Isg20-/- osteoblasts after IFN treatment, albeit with 5- to 100-fold 
difference in progeny virus at 24 hours p.i. (P < 0.01, Figure 23E).  
We sought to determine whether observed differences in virus replication can be attributed 
to differential regulation of ISG20-stimulated genes in primary cells. Using IFIT1 as a 
representative gene, we see a significant two-fold reduction in induction following low dose (10 
IU/mL) IFN priming in Isg20-/- MEFs (P < 0.05, Figure 23F). This reduction was abolished with 
high dose (100 IU/mL) IFN treatment (Figure 23F). These results are consistent with a model 
where ISG20 regulates the induction profile of ISGs and VSGs, providing antiviral activity against 
viruses in spatially separated subcellular compartments.  
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Figure 23: ISG20 Knockout Leads to Increased CHIKV and VEEV-G3A Replication in Primary Cells. 
(A) Isg20 induction was measured by qPCR in primary WT MEFs and osteoblasts by either IFN 
treatment or CHIKV infection. (B-E) Primary cells isolated from WT and Isg20-/- mice were assessed 
for (B-C) CHIKV and (D-E) VEEV-G3A replication competence with or without IFN priming. (F-
G) ISG induction was measured by qPCR in uninfected WT and Isg20-/- MEFs with or without IFN 
priming. * P < 0.05, ** P < 0.01, *** P < 0.001; (B-E) ANOVA, (n=6) (A,F-G) Mann-Whitney 
test. (n=6) 
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3.3 DISCUSSION 
Among the alphaviruses, CHIKV is highly susceptible to murine type I IFN responses with this 
effect being attributed to numerous individual effector proteins (167, 354, 365, 451-453). 
However, despite sensitivity to murine type I IFN, adult C57Bl/6J mice are susceptible to non-
lethal CHIKV disease, and mimic the arthritis phenotype observed in humans (168, 169). 
Disrupting signaling components of the type I IFN system, including IFNAR and STAT1, 
significantly increases CHIKV virulence, resulting in uniformly fatal disease in mice (169). 
Similarly, neonatal mice struggle to mount an effective innate immune response to infection, and 
are susceptible to fatal disease (167). Our findings with ISG20 overexpression in vitro would 
suggest that Isg20 deficiency should negatively impact the IFN-mediated antiviral response, 
leading to increased viral load, altered kinetics of viral spread, or varied pathological outcomes. 
However, in both non-lethal and lethal mouse challenge models, no differences were observed 
with CHIKV survival, disease symptoms or viral load.  
Both VEEV and EEEV infection are uniformly lethal in mice. VEEV infects rodents as a 
reservoir host and has evolved ways to circumvent the murine IFN response (14, 40). However, 
the VEEV-G3A mutant is attenuated in WT mice, but remains virulent in Ifit1-null mice (3). WT 
EEEV is also resistant to IFIT1 and dual G→A point mutations at positions 4 and 6 within the 5’-
NTR confer susceptibility to IFIT1 (Trobaugh et al., unpublished manuscript). Our in vitro 
findings indicate that ISG20 functions as a positive feedback regulator of antiviral factors, 
including IFIT1.  
The Isg20-/- mouse model revealed no significant difference in WT VEEV or EEEV 
infection, but trended toward earlier disease onset with WT VEEV infection. However, loss of 
Isg20 had a dramatic effect on both VEEV-G3A and EEEV-nt4&6 virulence in mice. Furthermore, 
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early after infection, Isg20-/- mice produced lower levels of IFN-α/β and some tissues (e.g., spleen) 
exhibited reduced IFN-β transcript levels in response to VEEV-G3A, which is consistent with 
ISG20 acting as a general stimulator of IRF3 and subsequently type I IFN. However, in ISG20 
overexpressing cells, IFN induction was not observed, although the cells were capable of 
responding to poly I:C transfection with IFN-α/β release. Additionally, a subset of Isg20-/- primary 
cells showed a greatly increased susceptibility to infection, even in the presence of IFN-priming. 
Ifit1 stands out as a prominent ISG20-regulated gene and a reduction in IFIT1 production would 
help explain the phenotypes of both VEEV-G3A and EEEV-nt4&6 in mice. Indeed, Ifit1 
transcription in response to IFN stimulation is impaired in Isg20-/- MEFs. Combined with our 
understanding of IFN-mediated Isg20 upregulation and downstream ISG20-mediated upregulation 
of IFIT1 and other antiviral effectors in vitro, the mouse model of VEEV-G3A supports a feedback 
mechanism of ISG20 to help stimulate sustained IFN and ISG production in response to infection. 
The failure of the overexpressing cells to produce IFN-α/β may instead reflect cell type-dependent 
differences in the effects of ISG20 or clonal adaptations to downregulate IFN production in 
response to ISG20. This is supported by primary cells that showed no effect on type I IFN induction 
levels (data not shown), which would suggest that IFN feedback regulation occurs in an 
unidentified cell type, possibly myeloid cells. 
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4.1 MODEL OF ISG20 ANTIVIRAL ACTIVITY 
The literature surrounding a mechanism for ISG20 antiviral activity is both incomplete and 
contradictory. When ISG20 was first characterized, genetic similarities to related DEXD nucleases 
and ex vivo biochemical analysis identified ISG20 as an IFN-induced 3’-5’ exonuclease with 
catalytic activity against single-stranded nucleic acids (400). ISG20 demonstrated a preference for 
ssRNA over ssDNA substrates, with no apparent sequence preference (400). Subsequently, ISG20 
antiviral activity against numerous RNA viruses was demonstrated through overexpression, but it 
failed to restrict the few DNA viruses tested, leading to the hypothesis that ISG20 actively targets 
and degrades RNA virus genomes and replicative intermediates (340-342, 405, 406, 411). This 
was further supported when it was discovered that a catalytically-dead mutant of ISG20 in the 
ExoII domain lost its antiviral activity against RNA viruses (405).  
ISG20 antiviral activity against RNA viruses is not uniform. For example, VSV was found 
to be potently inhibited by ISG20, but EMCV was notably more resistant (405). Further 
complicating matters, localization studies with ISG20 identified the sub-nuclear Cajal body as the 
primary cellular location for ISG20 (404). This compartmentalization of ISG20 would limit 
4.0  CONCLUSIONS 
 92 
exposure to many RNA viruses that replicate in the cytoplasm, including many with a known 
ISG20-restricted phenotype. The first direct evidence against ISG20-mediated virus degradation 
was demonstrated with HCV infection, where the authors found that ISG20 overexpression did 
not accelerate the decay of viral RNA at multiple time points post infection (411).  
Recently, the debate over ISG20-mediated viral nucleic acid-degradation as a mechanism 
for antiviral activity was renewed with two studies using HBV as a model (410, 444). HBV is a 
non-covalently-closed circular DNA virus, which replicates in the nucleus with a retrotranscribed 
RNA intermediate known as the pre-genome. Both studies demonstrated an accelerated decay of 
pre-genomic RNA in the presence of ISG20 overexpression, with the most recent demonstrating 
direct ISG20 binding to the viral RNA (410, 444). Interestingly, ISG20 was found to bind at the 
base of known stem-loop structures used to initiate virus replication, including one located away 
from the 3’-terminus (444). This study suggested a sequence-specific, or structure-specific, 
recognition of specific RNA motifs, facilitating ISG20 binding and degradation of the pre-genomic 
RNA. Furthermore, the catalytically inactive ExoII ISG20 mutant was capable of binding HBV 
pre-genomic RNA, and retained residual antiviral activity by obstructing encapsidation (444). The 
authors of this study proposed the most complete model of ISG20 antiviral activity to date, where 
ISG20 directly binds structural motifs within HBV and degrades pre-genomic RNA, inhibiting 
replication and translation of viral proteins, and restricting encapsidation.  
While there is growing support for the RNA degradation model, there is currently no 
evidence that ISG20 degrades RNA in the cytoplasm. Like HCV, the alphaviruses replicate their 
RNA genome entirely in the cytoplasm. Herein, we have demonstrated that both arthritogenic and 
encephalitogenic alphaviruses are subject to ISG20-mediated replication restriction. Furthermore, 
that restriction occurs at the point of early genomic translation of the genome-resident 
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nonstructural polyprotein. Our ISG20 translation inhibition phenotype depends on ExoII domain-
directed exonuclease activity, but does not extend to IRES-containing RNAs, strongly suggesting 
that ISG20 disrupts translation initiation rather than degrading cytoplasmic RNAs. This is 
consistent with previous findings with EMCV that showed a reduced ISG20-restriction phenotype 
compared to other RNA viruses (405). We further demonstrated that ISG20 does not accelerate 
the decay of the CHIKV 3’-terminus, and does not irreversibly modify synthetic reporter RNAs 
following prolonged exposure to overexpressed ISG20 in cells. Our results indicate that ISG20 
may instead utilize an alternative mechanism for restricting cytoplasmic RNA viruses, including 
the alphaviruses. It should be noted that a similar translation inhibitory activity was recently 
demonstrated for ISG20 in the context of FLUAV infection, a nuclear replicating RNA virus (409). 
However, the proposed mechanism is based on ISG20 binding to the FLUAV nucleoprotein and 
genomic RNA, much like the direct binding mechanism recently presented for HBV (409, 444).  
Despite our evidence suggesting ISG20 does not target viral RNA, an intact exonuclease 
domain is essential for its antiviral activities against the alphaviruses, which is similar to results 
published with the D94G ExoII mutant of ISG20 using other cytoplasmic RNA viruses. We have 
demonstrated that overexpressed ISG20, but not the ExoII mutant, modulates a pattern of gene 
regulation that closely resembles ISG and VSG induction by type I IFN. Furthermore, we have 
observed a reduction in select ISG induction by IFN in Isg20-/- primary cells compared to WT, 
strongly suggesting that ISG20 plays a fundamental role in regulating the robust expression of a 
subset of ISGs in response to low levels of IFN production. Our findings indicate that ISG20-
mediated gene regulation is IRF3-dependent, demonstrating a clear pathway for ISG20-mediated 
antiviral activities that extend beyond the nucleus. Interestingly, in mice, this pathway extended to 
a significant early upregulation of IFN production, but this effect is not observed in our 
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overexpression system. We attribute this discrepancy to potential clonal mutations or cell type-
specific regulatory activity within our inducible MEFs to circumvent sustained IFN production. 
While our ISG20 overexpressing MEFs respond to the RIG-I/MDA5 agonist, poly-(I:C), and 
produce IFN-α/β at similar levels to controls, notable IFN regulatory genes including Usp18 are 
induced by ISG20 overexpression, representing a possible pathway for the down-regulation of 
IFN.  
In contrast to the robust antiviral effect of ISG20 against WT alphaviruses in vitro, we 
observed little or no difference in the virulence of WT CHIKV, VEEV and EEEV in our mouse 
models of infection. Basal expression of Isg20 is minimal in most cell types, but it is strongly 
induced directly by IRF1 activation or through ISGF3 complex activation following IFN signaling. 
Likewise, an ISG20-mediated restriction in mice would be strongly dependent on the ability of a 
given virus to induce IFN. Both CHIKV and EEEV are weak inducers of IFN in mice, resulting in 
minimal detectible serum IFN within the first 24 hours of infection (14). However, VEEV robustly 
induces IFN shortly after infection, which is largely attributed to its strong tropism for myeloid 
cells (14). Thus, it is not surprising that a measurable phenotype was not observed with WT 
CHIKV and EEEV infection. In contrast, we did observe acute differences in VEEV clinical 
manifestations between B6 and Isg20-/- mice. While clinical differences were observed, survival 
was ultimately unaffected by Isg20 knockout.  
WT VEEV is resistant to the antiviral activity of IFIT1, owing this resistance to the terminal 
stem loop structure and positioning of the 5’ terminal type-0 cap (3). Our findings in vitro suggest 
that ISG20 induces Ifit1 among other genes, and is required for robust induction following IFN 
treatment in primary cells. Focusing on IFIT1 as a potential effector of the ISG20-mediated 
antiviral response, we assessed the virulence of VEEV-G3A, which is known to be sensitive to 
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IFIT1 activity in vitro and in vivo (3). Indeed, IFIT1-sensitivity resulted in a significant difference 
in VEEV virulence observed between B6 and Isg20-/- mice, supporting our model for ISG20 
regulation of other antiviral effectors. Furthermore, IFN is strongly induced between 12-24 hours 
– times at which differences in VEEV-G3A viral load are most apparent in tissues and serum.  
Interestingly, IFN was induced at significantly lower levels by VEEV-G3A at 12 hours p.i. 
in Isg20-/- compared to B6 mice. Our model of ISG20-mediated gene induction strongly implicates 
IRF3 as a signal transducer for downstream gene induction, which would include IFN-β among 
the targeted genes. While we observed no involvement in IFN induction or signaling in our 
overexpressed ISG20 model, our in vivo findings support a role for ISG20 in the positive feedback 
of type I IFN production in addition to specific gene induction, presumably through the same IRF3-
mediated pathway.  
Further supporting the direct involvement of IFIT1 as a mediator of the ISG20 response in 
vivo, virulence of EEEV-nt4&6, which has a similarly engineered susceptibility to IFIT1 as 
VEEV-G3A, was significantly decreased by ISG20 in mice. Unlike VEEV, EEEV largely evades 
myeloid cell replication, resulting in much lower levels of IFN induction in mice (125, 127). 
Consequently, EEEV-nt4&6 is not as sensitive VEEV-G3A to ISG20-mediated restriction in mice. 
However, EEEV-nt4&6 disease in Isg20-/- mice closely resembles that which is observed in Ifit1-/- 
mice (Trobaugh unpublished manuscript). Together, our in vivo findings with VEEV-G3A and 
EEEV-nt4&6 support a role for IFIT1 and a positive feedback regulation of IFN as contributors to 
the ISG20-mediated antiviral restriction of alphaviruses in animal models of disease. 
In conclusion, we propose a model by which induced ISG20 blocks incoming alphavirus 
genome translation through the modulation of additional antiviral ISGs and a more robust 
induction of type I IFN. This modulation of the host antiviral environment is achieved through the 
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direct activation of ISGs via IRF3 and, in vivo, a positive feedback loop of IFN production (Figure 
24). Given that ISG20 acts to degrade RNAs in the nucleosome and that the exonuclease domain 
is required for transcription-stimulating activity, it is tempting to speculate that these degradation 
products somehow activate the IRF3 pathway, perhaps by stimulating RIG-I or MDA5 RNA 
binding proteins. Additionally, ISG20 may not be increasing the nuclear translocation of IRF3, but 
instead may be preventing its deposphorylation or degradation. Such a mechanism would likely 
involve the down-regulation or inhibition of specific phosphatases and ubiquitin ligases. 
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Figure 24: ISG20 Antiviral Model 
A model for ISG20-mediated antiviral restriction of alphaviruses is given. Non-bolded black arrows 
represent published pathway nodes. Bolded black arrows are pathways nodes described in 
experimental detail herein. Red-dashed nodes are hypothetical and will be the focus of future work. 
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4.2 SECOND MESSENGER HYPOTHESIS 
ISG20 localizes to the sub-nuclear CB structures, and has been shown to co-precipitate in 
association with the U1 and U2 snRNAs of the spliceosome and U3 snoRNA required for 18S 
ribosomal RNA (rRNA) processing (404). ISG20 also specifically associates with the survival of 
motor neurons (SMN) protein within the nucleus, either through direct binding or in complex with 
the primary CB structural component, coilin (404). SMN acts as a binding platform for the 
assembly of Sm proteins with their associated uridine-rich snRNAs (454). The snRNAs and 
associated proteins are then assembled within CBs to form the functional spliceosome machinery 
responsible for intron removal and splicing of exons (446). Due to its close interaction with CB-
associated factors, it is likely that ISG20 is exposed to additional RNA substrates including 
additional small nuclear RNAs (snRNAs) as well as the small CB-specific RNAs (scaRNAs) and 
small nucleolar RNAs (snoRNAs) that interact with CB during biogenesis. 
The snRNAs, including U1 and U2 are transcribed by RNA polymerase II (Pol-II), and 
contain a 7-metylguanosine cap structure that is further modified as a 2,2,7-trimethylguanosine 
cap prior to nuclear import (455). One notable exception to the biogenesis pathway for snRNAs is 
U6, which is transcribed from RNA polymerase III (Pol-III), and contains a triphosphate motif at 
the 5’-terminus and 2’,3’-cyclic phosphate motif at the 3’-terminus (456, 457). Unlike the Pol-II-
transcribed snRNAs, U6 is retained in the nucleus throughout biogenesis and associates with the 
U4/U6 snRNP (456). The predicted secondary structure of U6 reveals a highly conserved 5’-stem-
loop structure including the 5’-terminal triphosphate nucleotide (458). However, 3’ secondary 
structures are fluid, and depend on intramolecular complexes formed between the U4 and U2 
snRNAs at different points in the splicing process (458). Thus, it is possible that the lack of 3’-
structure in U6 would allow for ISG20-mediated 3’-5’-degradation, producing a truncated hairpin 
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structure with a 5’-triphosphate and no 5’-terminal overhang. Such a degradation product would 
be free to diffuse from the associated splicing factors, with potential to interact with the cytosolic 
RNA sensors RIG-I and MDA5.  
RIG-I recognizes primarily 5’-triphosphate dsRNAs as well as type-0 capped dsRNAs 
lacking 2’-O-methylation (235, 236, 241, 459). RIG-I is not accommodating to 5’-terminal ssRNA 
overhangs, requiring substrates to be blunt ended, either in complex or as a terminal hairpin 
structure (241, 459, 460). Our proposed ISG20-directed U6 degradation product would fit the 
above criteria as an activator of RIG-I. In addition to truncated-U6 as a specific activator of RIG-
I, it is conceivable that other degradation products from the RNAs associated with CB and ISG20 
could serve as molecular second messengers for the cytoplasmic RNA sensors. Such an activation 
model would explain the downstream involvement of IRF3 as an ISG20 signal transducer, and is 
consistent with the requirement of ISG20 nuclease activity for ISG20-regulated gene stimulation 
and antiviral activity. Indeed, a similar involvement of RIG-I has been demonstrated for another 
cellular nuclease, RNase L, where cleaved self-RNAs amplify signaling through RIG-I (239). 
Another cytoplasmic RNA sensor, MDA5, recognizes primarily long, blunt-ended dsRNA without 
a terminal triphosphate or cap requirement (242). ISG20-mediated trimming of nuclear RNAs in 
complex, including the snRNAs of the spliceosome, could presumably result in blunt-ended RNA 
duplexes capable of MDA5 stimulation. 
4.3 NUCLEAR STABILITY HYPOTHESIS 
IRF3 is distributed throughout the cytoplasm of most cell types at rest. Upon pathogen-associated 
signal recognition, IRF3 is poly-phosphorylated by TBK1 and IKKε in its C-terminal 
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transactivation domain, stimulating dimerization and ultimately translocation into the nucleus 
where it acts as a transcription factor for IFN-β and other target genes (244, 461). IRF3 is 
inactivated by two distinct mechanisms, proteasomal degradation and PP2A/RACK1 mediated 
dephosphorylation (462, 463). Disruption of either of these pathways would lead to an aggregation 
of IRF3 within the nucleus, and prolonged transcription of IRF3-responsive genes. 
The exonuclease-deficient ISG20 mutant, ExoII, fails to induce antiviral gene transcription 
when overexpressed. It is therefore unlikely that ISG20 is regulating either of these pathways 
through protein-protein interactions. Instead, ISG20 may be regulating either of these through a 
nucleic acid intermediate. Transcriptional regulation could occur through ISG20-mediated mRNA 
degradation in the nucleus or perhaps through the regulation of long noncoding RNAs (lncRNA). 
lncRNAs are capable of regulating clusters of genes in a cis or trans fashion by binding nearby 
promoter elements to either up- or down-regulate transcription of genes through the rearrangement 
of histones or recruitment of basal transcription factors (464, 465). Indeed, ISG20 was shown to 
bind and modify HBV RNA within the nucleus, demonstrating an ability to interact with RNA 
substrates outside of the CB (444). However, transcriptional down-regulation of PP2A, RACK1 
or any of the ubiquitin E3 ligases was not detected by RNA-seq when ISG20 is overexpressed. 
Likewise, ISG20-mediated protein interactions that inhibit RACK1/PP2A complex formation is 
unlikely because ExoII, which only differs by a single amino acid in the catalytic site does not 
result in IRF3 accumulation.  
ISG20 interactions with spliceosome and nucleolar RNAs may point to the involvement of 
splicing or ribosome biogenesis. Splicing occurs as sequence elements in the nascent pre-mRNA 
transcripts are recognized by the small nuclear ribonucleoprotein particles of the spliceosome 
(466). A complex forms at the 5’ and 3’ end of an intron, mediated by specific interactions between 
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the snRNAs of each subunit, and facilitates intron lariat formation and excision (466). Exon 
selection is mediated by cellular conditions including cis- and trans-acting protein elements that 
favor which exons are used (466). Changes to the snRNAs of the spliceosome would result in 
global changes in splicing frequencies, likely decreasing splicing efficiency in cells where ISG20 
is overexpressed. While transcript variants were observed between ISG20 overexpressing and 
control cells, a pattern of global regulation was not apparent, with only 31 gene isoforms 
consistently regulated (data not shown). Likewise, impacts on ribosome biogenesis would likely 
have far-reaching consequences for ISG20 overexpressing cells and would likely not manifest as 
a targeted regulation of IRF3 phosphatases. While two potential approaches to IRF3-dependent 
gene transcription are possible, our data strongly suggests that ISG20 is not simply stabilizing 
IRF3 in the nucleus by preventing dephosphorylation and degradation, but rather points to a 
mechanism of activation and translocation.  
4.4 FUTURE DIRECTIONS 
Building on the framework of our model, future work should elucidate the extent to which IFIT1 
is responsible for ISG20-mediated alphavirus translation inhibition and whether alternative 
mechanisms are involved. WT alphaviruses are inhibited by overexpressed IFIT1 in vitro, but are 
not more virulent in Ifit1-/- mice (3, 340, 364). While translation suppression appears to be the 
primary mechanism of alphavirus restriction by ISG20, the breadth of antiviral effectors regulated 
by ISG20 would suggest additional points of intervention are likely involved. Many of the most 
highly induced genes from ISG20 stimulation have antiviral activity, but the mechanism is 
unknown. Using the narrow scope of ISG20-induced antiviral effectors, focus should be given to 
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studying the activity of these gene products. In addition to the ISG20 up-regulated factors, several 
down-regulated gene transcripts were identified by RNA-seq, including the structural components, 
collagen and laminin. While the primary focus should be placed on the antiviral effectors induced 
by ISG20, the functional consequences of the downregulated genes are nevertheless an interesting 
topic of study. Together, studies of both up- and down-regulated genes will provide a more 
complete understanding of how these factors are working together to suppress viral replication.  
Another important area of future study is the mechanism by which ISG20 is stimulating 
IRF3 involvement, and what additional pathways may be involved, including other IRFs induced 
downstream or independently of IRF3, including IRF7 and IRF9, both of which are upregulated 
by ISG20. Importantly, IRF3 transcriptional activity is facilitated by polyphosphorylation and 
translocation to the nucleus, two biological activities that should be explored in further detail in 
our ISG20 overexpression model. We hypothesize the involvement of a signaling pathway where 
ISG20 is producing a second messenger as a degradation product of cellular RNAs, similar to the 
RIG-I-mediated enhancement of IFN observed from active RNase L (239). The primary focus of 
such work should define the targets of ISG20 degradation, whether degradation products may 
function as second messengers, and what cellular factors are necessary for signal transduction. 
Such a pathway would involve the mitochondrial adapter MAVS as well as the cytosolic RNA 
sensors RIG-I or MDA5. Studies should address this pathway through overexpression of ISG20 in 
either Mavs-/-, Ddx58-/- (RIG-I) or Mda5-/- cells. While there is no clearly defined target for 
potential ISG20 degradation, the U6 snRNA would be a promising candidate for follow-up study 
due to its RNA structure and the predicted resulting degradation products.  
Additionally, ISG20-stimulated feedback of IFN appears to occur in vivo, and may 
contribute to the overall phenotypic differences observed between Isg20-/- and WT mice. Thus it 
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is necessary to determine whether low-level IFN production, below the limits of detection with 
our current methods, may be contributing to the antiviral gene pathways regulated by 
overexpressed ISG20 in vitro as our model would predict. While type I IFNs, particularly IFN-β, 
have been the focus of our work with ISG20, IFN-λ may account for a similar induction profile as 
we’ve observed with ISG20-overexpression, and should be the focus of additional studies as a 
mediator of antiviral gene upregulation. Combined with our current understanding of ISG20 as a 
regulator of antiviral gene transcription, a more complete understanding of ISG20 activity may 
lead to targeted antiviral therapies and serve as a foundation for rational vaccine design against the 
alphaviruses and other cytoplasmic-replicating viruses. 
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VIRUSES AND STOCKS 
Generation of the wild type La Réunion CHIKV-LR clone (467), a gift from Dr. Stephen Higgs, 
Kansas State University, and the non-structural reporter CHIKV-nsP3-(GFP/nLuc) clone or 
structural reporter CHIKV-TaV-(GFP/nLuc) (56) are previously described. The WT VEEV 
(ZPC738) and VEEV-G3A clones are described (468, 469). The WT EEEV (FL93-939) clone is 
described (470). EEEV-nt4&6 (FL93-939-G4A/G6A) was generated by QuickChange site-
directed mutagenesis of FL93-939 parental strain (Trobaugh, unpublished manuscript). Viruses 
were generated from in vitro transcribed infectious clones (mMessage mMachine, Ambion) and 
electroporated in BHK-21 cells. Supernatants were collected at 24 hours and centrifuged to remove 
cell debris prior to freezing individual use aliquots of each virus at -80ºC. All viral titers were 
determined by BHK-21 plaque assay and are expressed in PFU/mL. 
 
MICE AND INFECTIONS 
Male or pregnant female C57Bl/6J mice were purchased from the Jackson Laboratory. Isg20-/- 
mice were generated at Washington University after receiving heterozygous sperm from C57BL/6 
mice containing a promoter knockout (Isg20tm1a(KOMP)Wtsi) from the Knockout Mouse Project 
Repository (KOMP; University of California, Davis). Sperm was used for in vitro fertilization of 
eggs from C57BL/6 recipient female mice. Heterozygous Isg20+/− mice were backcrossed to 
5.0  MATERIALS AND METHODS 
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establish the Isg20-/- colony. Isg20-/- mice produced normal litter sizes of expected Mendelian 
ratios, with all progeny appearing healthy. Mice were used at ages 1 day or 3 weeks for CHIKV 
infection and an age of 6 weeks for VEEV infection. CHIKV (103 plaque forming units, PFU) was 
inoculated subcutaneously (sc) in the left rear footpad in 10 µL of OptiMEM. VEEV was 
inoculated sc in each rear footpad with 103 PFU for a total of 2x103 PFU per animal. Disease was 
monitored by changes in weight and clinical scoring specific to the disease manifestations of each 
virus every 12 to 24 h. For virus titration, RNA isolation and IFN bioassay, serum was collected 
from submandibular vein, and mice were euthanized and perfused with 10 mL of PBS before tissue 
collection. Tissues were collected in 100 uL of PBS with 1% bovine serum per gram of tissue, 
mechanically dissociated, and virus titers were determined by BHK-21 plaque assay on the 
resulting supernatants. Serum was assayed for functional type I IFN using a bioassay as previously 
described (208). All animal experiments were conducted under the guidance of approved protocols 
by the institutional animal care and use committee of the University of Pittsburgh. 
 
TET-OFF MEF CELL CULTURE 
Tet-off murine embryonic fibroblasts (MEFs) overexpressing ISG20 and eGFP control proteins 
were previously described and tet-off MEFs overexpressing ISG20D94G (ExoII) cells were 
generated in the same fashion (340). The ExoII gene was made by aligning the human sequence 
with the mouse sequence and mutation the active site of the exonuclease to match the human ExoII 
nuclease deficient mutant (405). Tet-off MEFs were maintained in complete media consisting of 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 200 mM L-glutamine, 10,000 units/mL penicillin, 10 mg/mL streptomycin, 
100 μg/mL G418 sulfate, and 100 μg/mL hygromycin sulfate. Gene overexpression was 
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suppressed with the addition of 2 μg/mL doxycycline hyclate (Sigma) for cell expansion prior to 
experiments.  
 
OVEREXPRESSION OF TARGET GENES 
 For overexpression experiments, tet-off MEFs were trypsinized and washed in sterile phosphate 
buffered saline three times and plated and induced in doxycycline-free, complete tet-off MEF 
media for 72 hours prior to use. Gene overexpression was confirmed by both qRT-PCR and 
Western blot for these conditions. All cells were grown to approximately 80% confluence for 
optimal infection and transfection conditions in subsequent experiments. 
 
GENERATION OF PRIMARY CELLS 
 Osteoblasts were prepared by dissecting calvaria from 4 day-old pups and manually removing 
surrounding tissue. Calvaria were washed in PBS and digested in two 20-minute and one 90-
minute digests in AMEM with 96 μg/mL collagenase P and 0.01% trypsin-EDTA on a shaking 
37°C incubator. Digested calvaria were washed in PBS and suspended in AMEM supplemented 
with 10% FBS, 10,000 units/mL penicillin, and 10 mg/mL streptomycin for 5 days undisturbed on 
100 mm cell culture dishes. Osteoblasts were trypsinized and expanded for two passages on T-75 
flasks prior to infections.  
Primary MEFs were prepared from pregnant mice at 14 days gestation. The head and liver 
was removed from individual embryos and specimens were rinsed in PBS. Embryos were minced 
in ice cold 0.25% trypsin-EDTA solution then heated to 37ºC for 30 minutes in a water bath. MEFs 
were homogenized by serial passage through 18 and 23 gauge needles. Cells were washed and 
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resuspended in DMEM supplemented with 10% heat-inactivated FBS, 10,000 units/mL penicillin, 
and 10 mg/mL streptomycin. MEFs were expanded to passage 2 for individual experiments. 
 
VIRUS GROWTH ASSAYS 
 50 µL of WT, non-reporter virus supernatant was drawn from infected cells at various times post 
infection and virus titer was determined by BHK-21 plaque assay. Nano luciferase reporter-virus 
infected cells were washed 3 times in PBS and lysed in luciferase passive lysis buffer then frozen 
to aid in complete disruption of cellular membranes. 25 μL of each sample lysate was combined 
with 25 μL of prepared NanoGLO chemiluminescent reagent and incubated for 6 minutes at room 
temperature. Chemiluminescent signal was detected on a luminometer as relative light units and 
normalized to individual sample protein concentrations determined by BCA protein assay. 
 
INTERFERON BIOASSAY 
Cleared serum or cell culture supernatant was acidified to pH=2.0 with 1M HCl and incubated for 
24 hours at 4°C. Samples were neutralized to pH=7.4 and serially diluted in 2-fold intervals in 
RPMI media supplemented with 10% FBS, 10% tryptose phosphate broth, 200 mM L-glutamine, 
10,000 units/mL penicillin, and 10 mg/mL streptomycin. Diluted samples were added to confluent 
L929 murine mesenchymal cells on 96-well cluster plates and incubated for 24 hours at 37°C with 
4% atmospheric CO2. Cells were infected with EMCV at MOI=0.5 added directly to the IFN 
sample-treated cells and incubated for an additional 24 hours. Cells were fixed and stained with 
1% crystal violet in 10% methanol for 15 minutes and washed to remove residual counterstain. 
IFN concentration was determined empirically against a standard dilution series of murine IFN-
α4/β (1:1) of known concentration based on protection from cytopathic effect. 
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TRANSLATION REPORTERS 
 The non-replicating host, EMCV and CHIKV virus-mimic translation reporters were described, 
or produced as described (127, 339). The CrPV translation reporter, a gift from Dr. Martin Bushell, 
Medical Research Council, UK, was described (471). Tet-off MEFs were induced on 150mm 
dishes as described above for overexpression of the contained gene of interest.  Induced cells were 
trypsinized and washed once in OptiMEM. Approximately 3x107 cells were resuspended in 1 mL 
of OptiMEM per reaction and electroporated with 7.5 μg of indicated reporter RNA and 750 ng of 
renilla luciferase mRNA. Electroporated cells were diluted in doxycycline-free MEF complete 
media and divided on 96-well cluster plates. Cells were collected at the indicated time points by 
centrifugation, washed once in PBS, and lysed in luciferase passive lysis buffer 0.25 μL of 
collected lysates were assayed by Dual Luciferase Assay (Promega) and normalized to protein 
concentration as determined by BCA protein assay (Thermo Scientific).  
 
PROMOTER ACTIVATION REPORTERS 
 Construction of promoter luciferase plasmids pRL-SV40, pβLUX, a gift form Dr. Barbara Sherry, 
North Carolina State University, (472), PRDI/III or PRDII, gifts form Dr. Tom Maniatis, Harvard 
University (245), were described previously. MEFs were induced in 24-well cluster plates for 
overexpression of the target protein for 3 days as described above. 0.5 µg/well of promoter 
luciferase plasmid and 0.25 µg/well of Renilla luciferase control plasmid were transfected into 
MEFs using TransIT-LT1 reagent (Mirus) for 24 hours. Cells were treated 16 hours prior to harvest 
with 0.3 µg poly-(I:C) in TransIT-LT1 reagent or transfection reagent alone. Lysates were 
collected in passive lysis buffer and measured by dual luciferase assay (Promega) and results given 
as a ratio of firefly to renilla luciferase signal. 
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RNA SEQUENCING 
Total cellular RNA from two separately derived clones of tet-off MEFs overexpressing eGFP, 
ISG20 or ISG20D94G was isolated and depleted of ribosomal RNA with the Ambion RiboMinus 
Eukaryote Kit v2 (Life Technologies). Directional sequencing libraries were generated using the 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina with NEBNext Primer Set 1 (New 
England Biolabs). Multiplexed libraries were sequenced with 100bp paired end reads on the 
Illumina HiSeq2000 platform (Axeq Technologies). Reads were aligned to the iGenome indexed 
Mus musculus genome UCSC mm9 (Illumina) using Tophat and differential gene expression was 
determined using Cufflinks (473). Pathway analysis of differentially-regulated genes was 
performed using Ingenuity Pathway Analysis (Qiagen) with a minimum read threshold of 10 
counts. 
 
QRT-PCR 
Forward and reverse primers for qRT-PCR were designed as follows: Isg20-F 5’-AAC ATC CAG 
AAC AAC TGG CGG-3’; Isg20-R 5’-GTC TGA CGT CCC AGG GCA-3’; Irgm2-F 5’-GCG 
ATA GAG ATT CGG AAA GC-3’; Irgm2-R 5’-CAG CAC CCA GTC ATC TTG TT-3’; Usp18-
F 5’-AGG AGT CCC TGA TTT GCG TG-3’; Usp18-R 5’-GGG TTT TCA GAG GCT TTG CG-
3’; Ifit3-F 5’-AGA TTT CTG AAC TGC TCA GCC C-3’; Ifit3-R 5’-CAG AGA TTC CCG GTT 
GAC CTC-3’; Irf7-F 5’-ATT TCG GTC GTA GGG ATC TG-3’; Irf7-R 5’-GTT GGT CTT CCA 
GCC TCT TC-3’; Ifi44-F 5’-ACT CGT TTG ACA TGG CAG CA-3’; Ifi44-R 5’-TCT GCA CAC 
TCG CCT TGT AA-3’; Ifit1-F 5’-GTG GCT CAC ATA GAG CAG GA-3’; Ifit1-R 5’-AGT TTC 
CTC CAA GCA AAG GA-3’; Oas1a-F 5’-TCC ACA GTA CGC CCT AGA GT-3’; Oas1a-R 5’-
GAC CAG TTC CAA GAC GGT CC-3’; Igtp-F 5’-TCT GAG CAG GTT CTG AAG GA-3’; Igtp-
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R 5’-TCC TCG GCT TCT TTC TTC TC-3’; Isg15-F 5’-TCC ATG ACG GTG TCA GAA CT-3’; 
Isg15-R 5’-GAC CCA GAC TGG AAA GGG TA-3’; Ifit2-F 5’-AGA ATT CAC CTC TGG ATG 
GG-3’; Ifit2-R 5’-GTC AAG CTT CAG TGC CAA GA-3’; Irf3-F 5’-GCG GTT AGC TGC TGA 
CAA TA-3’; Irf3-R 5’-AGG CCA TCA AAT AAC TTC GG-3’; CHIKV-3’NTR-F 5’-ATA ATT 
GGC AAA CGG AAG AGA T-3’; CHIKV-3’NTR-R 5’-ACA AAA TAA CAT CTC CTA CGT 
CC-3’. qRT-PCR primers for CHIKV positive strand detection were previously described (474). 
cDNA was reverse transcribed with specific reverse primers from 100 ng of tri-reagent-extracted 
RNA and detected by qPCR with SYBR green on a MiniOpticon thermal cycler and detection unit 
(Bio Rad). Fold-induction was determined for genes of interest using the ∆∆Ct method. 
 
WESTERN BLOT 
 MEFs were induced for 72 hours as described above then lysed completely in radio 
immunoprecipitation assay buffer with protease and phosphatase inhibitors. Cell wall debris was 
cleared by centrifugation and 20ng of protein were electrophoresed on 5%/10% SDS poly-
acrylamide discontinuous gels. Gels were transferred to polyvinylidene difluoride (PVDF) 
immunoblotting membrane by semi-dry transfer and blocked with 5% non-fat milk in tris-buffered 
saline with 0.1% Tween-20 (TBS-T) for 1 hour. Anti-FLAG M2-Peroxidase conjugate (1:2000) 
was applied for 2 hours at room temperature, or rabbit anti-mIFIT1 (1:1000) was applied overnight 
at 4ºC with shaking. Secondary detection of IFIT1 was performed by thoroughly washing in TBS-
T followed by goat anti-rabbit-HRP conjugate (1:2000) for 1 hour at room temperature. Blots were 
thoroughly washed prior to detection with Pierce ECL detection reagent (Thermo Scientific) and 
chemiluminescence film exposure (GE Healthcare). 
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IMMUNOFLUORESCENCE  
Cells grown on glass coverslips were fixed in 4% paraformaldehyde for 15 minutes and 
permeablized with 0.1% Triton X-100 in PBS for 15 minutes. Fixed cells were rehydrated in PBS 
with 0.5% BSA (PBS-B) and blocked for 45 minutes in 20% serum in PBS-B, corresponding to 
the secondary detection antibody species. Primary and secondary detection antibodies were 
applied for 1 hour each at room temperature in PBS-B. Immunofluorescence was preserved with 
SlowFade Gold antifade reagent with DAPI (Invitrogen) and mounded on glass slides for confocal 
microscopy. M2 anti-FLAG FITC conjugate antibody (Sigma) was used for detection of both 
FLAG-tagged murine ISG20 and ISG20D94G. 
 
STATISTICS 
All statistics were calculated in GraphPad PRISM with α = 0.05. Hypotheses for mRNA 
expression levels were calculated by two-tailed Mann-Whitney test on log10-transformed fold-
change values. Parametric hypotheses with assumed standard deviations were calculated by 
multiple Student’s t tests. Hypotheses for virus growth curves, reporter expression ratios, and 
percent of starting value were calculated on log10-transformed datasets by two-way ANOVA, 
correcting for multiple comparisons using the Holm-Sidak method, or ANOVA, correcting for 
multiple comparisons using Dunnett’s method. Survival hypotheses were tested by log-rank test. 
The statistical model for differential gene expression by RNA-seq is described in detail (475). The 
Cuffdiff 2 gene expression model was determined for a false discovery rate of 5%. 
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ATF-2  Activating transcription factor 2 
BHK-21  Baby hamster kidney cell [clone C-13] 
c-Jun  Early response transcription factor 
CARD  Caspase activation and recruitment domain 
CB  Cajal body 
CBP  CREB-binding protein 
cGAMP  Cyclic guanosine/adenosine monophosphate 
cGAS  Cytosolic GAMP synthase 
CHIKV  Chikungunya virus 
CrPV  Cricket paralysis virus 
DBS  Donor bovine serum 
DMEM  Dulbecco’s Modified Eagle Medium 
DNA  Deoxyribonucleic acid 
EEEV  Eastern equine encephalitis virus 
eGFP  Enhanced green fluorescent protein 
EMCV  Encephalomyocarditis virus 
ExoII  ISG20 aspartic acid 94 to glycine mutation of exonuclease active site domain 2 
FBS  Fetal Bovine Serum 
IFIT  Interferon induced protein with tetratricopeptide repeats 
IFN  Interferon 
IFNAR  Interferon alpha receptor 
IKKε  IκB kinase-ε 
IRAK  Interleukin-1 receptor-associated kinase 
APPENDIX A 
DEFINITIONS 
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IRF  Interferon regulatory factor 
ISG  Interferon-stimulated gene 
Isg20  Murine 20 kilodalton interferon-stimulated gene (gene) 
ISG20  Human or mouse 20 kilodalton interferon-stimulated gene (protein) 
Isg20-/-  Homozygous Isg20-null genotype 
ISGF  Interferon-stimulated gene factor complex 
JAK  Janus kinase 
kDa  kilodalton 
L-929  NCTC clone 929 subcutaneous connective cell derived from strain L 
lncRNA  Long non-coding RNA 
MAVS  Mitochondrial antiviral signaling protein 
MDA5  Melanoma differentiation-associated gene 5 
MEF  Murine embryonic fibroblast cell 
MyD88  Myeloid differentiation primary response protein 88 
NFκB  Nuclear factor-κB 
NLR  NOD-like receptors 
nLuc  Nano-luciferase 
NOD  Nucleotide-binding oligomerization domain-containing protein 
nsP  non-structural protein 
NTR  Non-translated region 
p300  E1A binding protein 
PAMP  Pathogen associated molecular pattern  
Pol   RNA polymerase (I, II, or III) 
PRR  Pattern recognition receptor 
qRT-PCR  Quantitative reverse-transcription polymerase chain reaction 
RIG-I  Retinoic acid inducible gene 1 (also Ddx58) 
RLR  RIG-I-like receptor 
RNA  Ribonucleic acid 
RPMI  Roswell Park Memorial Institute 1640 Media 
scaRNA  Small Cajal body associated RNA 
SINV  Sindbis virus 
siRNA  Small-interference ribonucleic acid 
snoRNA  Small nucleolar RNA 
snRNA  Small nuclear RNA 
snRNP  Small nuclear ribonucleoprotein particle 
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ssRNA  Single-stranded ribonucleic acid 
STAT  Signal transducer and activator of transcription 
STING  Stimulator of IFN genes 
SV  Sendai virus 
TaV  Thosea assigna virus 2A-like cleavage signal peptide 
TBK1  TANK-binding kinase 1 
Tet  Tetracycline 
Tet-off  Tetracycline removal-induction system 
TLR  Toll-like receptor 
TRAF  (Tumor Necrosis Factor) receptor-associated factor 
TRIF  TIR domain-containing adapter protein inducing IFN-β 
TYK-2  Tyrosine kinase 2 
VEEV  Venezuelan equine encephalitis virus 
VSG  Virus Stimulated Gene 
WT  Wild type 
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Gene 
Name Gene ID Gene Description Protein Class log(ISG20/GFP) log(ISG20/ExoII) 
Apol9b 71898 Apolipoprotein 9b apolipoprotein 1.131 1.908 
Apol9a 223672 Apolipoprotein 9a apolipoprotein 0.894 1.573 
Apol10b 328561 Apolipoprotein 10b apolipoprotein 0.691 0.871 
Ccl7 20306 C-C motif chemokine 7 chemokine 0.669 0.775 
Ccl2 20296 C-C motif chemokine 2 chemokine 0.628 0.964 
Ddx58 230073 ATP-dependent RNA helicase RIG-I 
cytoplasmic RNA 
sensor 0.834 0.763 
Has2 15117 Hyaluronan synthase 2 glycosyltransferase 0.707 0.477 
Irgm2 54396 Interferon-gamma induced GTPase GTPase 1.697 1.367 
Igtp 16145 Interferon-gamma induced GTPase GTPase 1.119 1.189 
Irgm1 15944 
Immunity-related 
GTPase family M 
protein 1 
GTPase 0.663 0.375 
Ifit3b 667370 
Interferon-induced 
protein with 
tetratricopeptide 
repeats 3B 
IFIT protein 1.451 1.100 
Ifit1 15957 
Interferon-induced 
protein with 
tetratricopeptide 
repeats 1 
IFIT protein 1.440 1.540 
Ifit3 15959 
Interferon-induced 
protein with 
tetratricopeptide 
repeats 3 
IFIT protein 1.256 0.956 
Xaf1 327959 XIAP-associated factor 1 metal ion binding 0.825 0.815 
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Trim30a 20128 
Tripartite motif-
containing protein 
30A 
nucleic acid binding 1.465 1.557 
Trim12c 319236 Tripartite motif-containing 12C nucleic acid binding 1.118 0.702 
Parp14 547253 Poly [ADP-ribose] polymerase 14 nucleotidyltransferase 1.297 1.031 
Oasl2 23962 
2'-5'-oligoadenylate 
synthase-like protein 
2 
nucleotidyltransferase 1.165 1.926 
Parp9 80285 Poly [ADP-ribose] polymerase 9 nucleotidyltransferase 0.946 0.668 
Pde1b 18574 
Calcium/calmodulin-
dependent 3',5'-
cyclic nucleotide 
phosphodiesterase 
1B 
phosphodiesterase 1.156 0.846 
Samd9l 209086 
Sterile alpha motif 
domain containing 
9-like 
protein binding 1.381 0.849 
Lgals3bp 19039 Galectin-3-binding protein protein binding 0.789 0.792 
Lncenc1 100039691 
Long non-coding 
RNA, embryonic 
stem cells expressed 
1 
regulator of gene 
expression 0.920 0.712 
Irf7 54123 Interferon regulatory factor 7 transcription factor 1.343 1.354 
Stat1 20846 
Signal transducer 
and activator of 
transcription 1 
transcription factor 0.596 0.570 
Stat2 20847 
Signal transducer 
and activator of 
transcription 2 
transcription factor 0.574 0.522 
Irf9 16391 Interferon regulatory factor 9 transcription factor 0.486 0.575 
Tap1 21354 Antigen peptide transporter 1 transport protein 0.531 0.536 
Isg15 100038882 Ubiquitin-like protein ISG15 ubiquitin-like protein 0.925 1.645 
Dtx3l 209200 E3 ubiquitin-protein ligase DTX3L 
ubiquitin-protein 
ligase 0.979 0.621 
Herc6 67138 E3 ISG15--protein ligase Herc6 
ubiquitin-protein 
ligase 0.789 0.434 
Ifi44 99899 Interferon-induced protein 44 unassigned 1.483 1.673 
Xlr 22441 
X-linked 
lymphocyte-
regulated protein 
PM1 
unassigned 1.296 0.648 
Sp140 434484 Sp140 nuclear body protein unassigned 0.930 0.688 
Bst2 69550 Bone marrow stromal antigen 2 unassigned 0.798 1.082 
Ifi35 70110 Interferon-induced 35 kDa protein unassigned 0.503 0.620 
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Table 2: ISG20-Upregulated Genes 
Illumina directional libraries were generated from ribosomal RNA-depleting total cellular RNA from 
MEFs overexpressing eGFP, ISG20, and ExoII mutant. 100 bp paired-end deep sequencing was 
performed on HighSeq 2000 (Illumina). Differential gene expression was determined by Tuxedo 
Suite pipeline and genes significantly upregulated by ISG20 overexpression versus both eGFP and 
ExoII controls. Common gene names were matched to mm9 genome loci and RefSeq gene IDs, gene 
descriptions and protein classes were determined by PANTHER classification system with 
additional manual curation. 
 118 
Gene 
Name Gene ID Gene Description Protein Class log(ISG20/GFP) log(ISG20/ExoII) 
Sorbs2 234214 
Sorbin and SH3 
domain-containing 
protein 2 
cytoskeletal protein -1.190 -0.936 
Col2a1 12824 Collagen alpha-1(II) chain 
extracellular matrix 
linker protein -1.298 -1.590 
Lama2 16773 Laminin subunit alpha-2 
extracellular matrix 
linker protein -1.498 -1.860 
Bmp4 12159 Bone morphogenetic protein 4 growth factor -0.769 -0.824 
Peg10 170676 
Retrotransposon-
derived paternally 
expressed 10 
nucleic acid binding -0.692 -0.735 
Pde8a 18584 
High affinity 
cAMP-specific and 
IBMX-insensitive 
3',5'-cyclic 
phosphodiesterase 
8A 
phosphodiesterase -0.737 -0.920 
Xist 213742 Inactive X specific transcripts 
ribonucleoprotein 
complex binding -0.896 -1.204 
Table 3: ISG20-Downregulated Genes 
APPENDIX C 
ISG20-DOWNREGULATED GENES 
Illumina directional libraries were generated from ribosomal RNA-depleting total cellular RNA from 
MEFs overexpressing eGFP, ISG20, and ExoII mutant. 100 bp paired-end deep sequencing was 
performed on HighSeq 2000 (Illumina). Differential gene expression was determined by Tuxedo 
Suite pipeline and genes significantly downregulated by ISG20 overexpression versus both eGFP 
and ExoII controls. Common gene names were matched to mm9 genome loci and RefSeq gene IDs, 
gene descriptions and protein classes were determined by PANTHER classification system with 
additional manual curation. 
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Upstream 
Regulator 
Molecule 
Type 
Predicted 
Activation 
State 
Activation 
z-score 
p-value 
of 
overlap 
Target molecules in 
dataset 
Mechanistic 
Network 
IFNAR group Activated 4.305 1.34E-23 
Bst2, Ccl2, CCL5, 
CXCL10, DDX58, 
EIF2AK2, IFI35, IFIH1, 
IFIT1B, IFIT2, IFIT3, 
Irgm1, ISG20, OAS1, 
PNPT1, STAT1, STAT2, 
USP18, XAF1 
53 (18) 
IRF7 transcription regulator Activated 4.666 1.73E-23 
ADAR, CCL5, CXCL10, 
DDX58, IFI35, IFI44, 
IFIH1, IFIT1B, IFIT2, 
IFIT3, Igtp, Irgm1, 
ISG15, ISG20, OAS1, 
Oasl2, RTP4, SAMD9L, 
STAT1, STAT2, 
Trim30a/Trim30d, 
USP18, XAF1 
43 (13) 
RIG-I enzyme Activated 3.243 4.31E-22 
Ccl2, CCL5, CXCL10, 
DDX58, EIF2AK2, IFI35, 
IFI44, IFIH1, IFIT1B, 
IFIT2, IFIT3, ISG15, 
ISG20, OAS1, STAT1, 
STAT2 
42 (13) 
IRF3 transcription regulator Activated 4.044 5.54E-19 
Ccl2, CCL5, CXCL10, 
DDX58, IFI44, IFIH1, 
IFIT1B, IFIT2, IFIT3, 
Igtp, Irgm1, ISG15, 
ISG20, OAS1, Oasl2, 
SAMD9L, STAT1, 
STAT2, 
Trim30a/Trim30d, USP18 
39 (14) 
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MAVS other Activated 3.395 7.62E-17 
ADAR, CCL5, CXCL10, 
DDX58, IFIT1B, IFIT2, 
IFIT3, ISG15, ISG20, 
OAS1, Oasl2, STAT1, 
STAT2 
42 (11) 
IFN-λ1 cytokine Activated 3.719 1.40E-16 
CXCL10, DDX58, 
EIF2AK2, IFI35, IFI44, 
IFIH1, IFIT2,IFIT3, 
ISG15, ISG20, 
LGALS3BP, OAS1, 
STAT1, USP18 
47 (12) 
IFN-β group Activated 3.781 1.83E-15 
CXCL10, DDX58, 
EIF2AK2, IFI35, IFI44, 
IFIH1, IFIT1B, IFIT2, 
IFIT3, ISG15, OAS1, 
PNPT1, STAT1, STAT2, 
USP18, XAF1 
59 (17) 
IRF5 transcription regulator Activated 3.539 1.86E-15 
CCL5, CXCL10, DDX58, 
IFI44, IFIH1, IFIT2, 
IFIT3, ISG15, ISG20, 
OAS1, Oasl2, STAT1, 
STAT2 
44 (18) 
TLR3 transmembrane receptor Activated 2.634 9.60E-15 
Ccl2, CCL5, Ccl7, 
CXCL10,DDX58, 
EIF2AK2, Ifi202b, IFI44, 
IFIH1, IFIT2, IFIT3, 
ISG15, ISG20, OAS1, 
Oasl2, PTX3, STAT1, 
TNC, USP18 
47 (14) 
IFN-α group Activated 4.253 5.48E-14 
ADAR, BMP4, Bst2, 
CCL5, CXCL10, DDX58, 
EIF2AK2, F3, IFI35, 
IFIH1, IFIT1B, IFIT2, 
IFIT3, ISG15, ISG20, 
OAS1, PNPT1, SREBF2, 
STAT1, STAT2, USP18 
49 (15) 
Table 4: Predicted Upstream Effectors of ISG20 Gene-Regulation Pathway  
ISG20-upregulated genes determined by RNA sequencing were imported to Ingenuity Pathway 
Analysis and analyzed for probable upstream effectors in an activated state. Predicted effectors 
include both individual transcription factors, defined signaling pathways, and receptors. 
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